AKTX
Akari Therapeutics
$1.58Tn
11.29
+4.15%
-56.91%
Akari Therapeutics develops antibody-drug conjugates (ADCs), which are biologics consisting of antibodies linked to payloads. The company's revenue model is based on the future sale of these biologic products, as well as licensing, milestones, and royalties from biopharmaceutical partners.
LLY
Eli Lilly
$1.08Tn
1,148.74
-0.93%
+55.69%
Eli Lilly discovers, develops, manufactures, and markets branded prescription drugs across therapeutic areas such as cardiometabolic health, oncology, immunology, and neuroscience. Its revenue is primarily generated from the sale of branded pharmaceutical products like insulin analogs and GLP-1 receptor agonists.
JNJ
Johnson & Johnson
$663.08Bn
275.15
-1.19%
+54.58%
The company's Innovative Medicine segment generates significant revenue from branded prescription pharmaceuticals such as STELARA, TREMFYA, and XARELTO. These products are sold to retailers, wholesalers, and hospitals for the treatment of oncology, immunology, and cardiovascular diseases.
ABBV
AbbVie
$453.04Bn
256.37
-1.48%
+20.36%
AbbVie is a diversified pharmaceutical company that develops and markets branded prescription drugs across multiple therapeutic areas. Its revenue is driven by branded products such as Vraylar, Ubrelvy, Qulipta, and Mavyret.
MRK
Merck
$370.87Bn
150.32
-1.33%
+78.85%
Merck's primary revenue driver is the sale of branded prescription pharmaceuticals and vaccines for human health, with 2025 pharmaceutical sales totaling $58,142 million. Key branded products cited include Keytruda, Gardasil, and Januvia.
UNH
Unitedhealth
$359.38Bn
397.10
-0.96%
+28.98%
UnitedHealthcare is a major provider of health benefit plans, including employer-sponsored, Medicare Advantage, and Medicaid-focused products, generating significant premium revenues from CMS and other payers.
NVS
Novartis Ag
$305.29Bn
159.99
-1.89%
+24.58%
Novartis is an innovative medicines company that researches, develops, manufactures, and markets branded prescription pharmaceuticals across therapeutic areas such as cardiovascular, renal, metabolic diseases, immunology, neuroscience, and oncology. Its primary revenue is generated from the sale of these pharmaceutical products to wholesalers, health systems, and government agencies.
AMGN
Amgen
$236.37Bn
437.23
-1.55%
+56.10%
Amgen is explicitly described as a leading independent biotechnology company that researches, develops, and commercializes therapies derived from biological science. Its revenue is generated from the sale of therapeutic medicines such as Enbrel and Repatha, which are biologic products.
TMO
Thermo Fisher Scientific
$226.93Bn
613.75
-0.75%
+25.39%
The company's Life Sciences Solutions and Analytical Instruments segments provide a vast portfolio of reagents, instruments, and consumables for biological and medical research, genomic and proteomic analysis, and electron microscopy. These products are sold to universities, research institutions, and biotech firms to support scientific research and bioproduction.
NVO
Novo Nordisk A S
$223.78Bn
46.62
-1.89%
-17.84%
Novo Nordisk discovers, develops, and markets branded prescription pharmaceuticals, specifically GLP-1 receptor agonists like Ozempic and Wegovy for obesity and diabetes. Its revenue is primarily generated from the sale of these branded pharmaceutical products.
ABT
Abbott Laboratories
$187.42Bn
108.31
-0.44%
-18.45%
Abbott develops and sells a wide range of therapeutic medical devices, including pacemakers, defibrillators, stents, and glucose monitors, sold to hospitals and physicians.
GILD
Gilead Sciences
$187.38Bn
150.99
-0.15%
+33.63%
Gilead is a biopharmaceutical company that develops therapies derived from biological science, including monoclonal antibodies and CAR T cell therapies like Yescarta and Tecartus. Its revenue is driven by the sale of these biologic products and royalties from collaborations.
PFE
Pfizer
$162.10Bn
28.44
-1.32%
+15.89%
Pfizer is a global biopharmaceutical company that discovers, develops, and markets a vast portfolio of branded prescription drugs and vaccines, including Eliquis, Prevnar, and Paxlovid. Its primary revenue is generated from the sale of these branded pharmaceutical products to hospitals, patients, and healthcare providers.
DHR
Danaher
$145.94Bn
207.62
-1.60%
+4.32%
Danaher's Life Sciences and Biotechnology segments provide instruments, consumables, and software for bioprocessing, genomics, and proteomics used in laboratory research and biopharmaceutical manufacturing. These products are sold to research institutions and biotech companies to study biological molecules like DNA and RNA.
VRTX
Vertex Pharmaceuticals
$138.36Bn
546.12
-2.12%
+37.69%
Vertex is described as a global biotechnology company that develops therapies derived from biological science, including proteins and biologics. Its revenue is derived from the sale of biologic products, collaboration milestone payments, and royalties.
BMY
Bristol Myers Squibb
$136.51Bn
66.83
-1.85%
+40.69%
Bristol Myers Squibb is a large pharmaceutical firm that discovers, develops, and markets a wide portfolio of branded prescription medicines such as Eliquis, Sprycel, and Abraxane. Its revenue is primarily generated from the sale of these innovative branded pharmaceuticals across multiple therapeutic areas.
ISRG
Intuitive Surgical
$129.78Bn
366.70
-0.85%
-16.88%
Intuitive Surgical designs and manufactures robotic assisted surgical systems, specifically the da Vinci and Ion platforms, which are used for minimally invasive procedures. These are therapeutic and surgical medical devices sold to hospitals and ambulatory surgery centers.
CVS
Cvs Health
$123.65Bn
96.75
-0.45%
+31.96%
The company generates its primary revenue from insurance premiums through its Health Care Benefits segment, which offers medical, dental, and vision plans including Medicare Advantage and Medicaid. It also operates a leading pharmacy benefit manager (PBM) through CVS Caremark, which is explicitly listed under the Managed Care industry definition.
MDT
Medtronic
$120.53Bn
94.16
+1.13%
+2.07%
Medtronic designs and manufactures a vast array of therapeutic and surgical medical devices, including implantable cardiac pacemakers, defibrillators, spinal implants, and robotic-assisted surgery systems. These products are sold to hospitals and physicians for the treatment of cardiovascular, neuroscience, and surgical conditions.
MCK
Mckesson
$105.79Bn
907.35
-1.50%
+31.22%
McKesson's primary revenue is generated through the wholesale distribution of branded, generic, specialty, and biosimilar pharmaceutical drugs, as well as medical-surgical supplies. It serves a massive network of retail pharmacies, hospitals, and institutional healthcare providers as a critical intermediary in the supply chain.
ELV
Elevance Health
$88.36Bn
407.50
-1.74%
+26.71%
Elevance Health operates as one of the largest health insurers in the U.S., generating primary revenue through risk-based premiums from medical plans for individuals, employer groups, Medicaid, and Medicare. It provides managed care plans and administrative services, which is the core definition of the Managed Care industry.
HCA
HCA Healthcare
$88.28Bn
405.01
-1.04%
-1.60%
HCA Healthcare operates a vast network of 190 hospitals, including 179 general acute care hospitals with over 50,000 licensed beds, as well as behavioral and rehabilitation hospitals. Its primary revenue is generated from facility-based inpatient and surgical care reimbursed by Medicare, Medicaid, and private insurers.
REGN
Regeneron Pharmaceuticals
$85.09Bn
827.72
-1.87%
+45.93%
Regeneron is a biotechnology company that develops and commercializes therapies derived from biological science, specifically using its VelociSuite and Trap technology to produce fully human antibodies and bispecific molecules. Its revenue is driven by the sale of biologic products such as EYLEA, Dupixent, and Libtayo, as well as collaboration and royalty payments.
CI
Cigna
$74.65Bn
282.52
-1.28%
-7.07%
Cigna generates significant revenue from premiums and administrative fees for medical and health insurance plans through its Cigna Healthcare segment. It provides employer medical plans, individual and family plans, and international health coverage, which are core managed care activities.
BSX
Boston Scientific
$69.29Bn
47.81
+1.83%
-55.54%
Boston Scientific designs and manufactures therapeutic and surgical medical devices, including stent systems, catheters, implantable pacemakers, and neurostimulation platforms. These products are sold to hospitals and clinics for use in cardiovascular, respiratory, digestive, oncological, neurological, and urological conditions.
ARGX
Argenx Se
$63.93Bn
1,033.15
-1.93%
+40.82%
Argenx is a biopharmaceutical company that develops and commercializes antibody-based therapeutics, such as VYVGART, which is an FcRn inhibitor. Its revenue is derived from the sale of these biologic products and from milestone payments and royalties from collaborations with partners like Zai Lab and AbbVie.
COR
Cencora
$63.13Bn
330.85
-1.87%
+12.10%
Cencora is a leading global pharmaceutical distributor that generates the majority of its revenue from the sale of pharmaceutical products to hospitals, health systems, physician practices, and retail pharmacies. Its core business involves delivering brand, generic, and specialty drugs from manufacturers to dispensers.
TEL
2nd
TE Connectivity
$60.39Bn
208.59
-0.40%
+0.02%
The company manufactures interventional medical components and products for medical imaging, diagnostic, surgical, and minimally invasive applications.
MRNA
Moderna
$58.07Bn
145.55
-2.23%
+505.20%
Moderna is a biotechnology company that researches and commercializes therapies derived from biological science, specifically messenger RNA (mRNA). Its revenue is generated from the sale of biologic products like Spikevax and mRESVIA, as well as collaboration and licensing revenue.
CAH
Cardinal Health
$57.48Bn
247.13
-0.56%
+64.14%
Cardinal Health's primary revenue is generated through the wholesale distribution of branded and generic pharmaceuticals, over-the-counter products, and specialty pharmaceuticals to retailers and hospitals. This is the core activity of its Pharmaceutical and Specialty Solutions segment.
AME
2nd
Ametek
$54.50Bn
237.70
+1.55%
+28.94%
The Electromechanical group designs and manufactures medical devices, including surgical instruments and implantable devices, sold to medical device makers.
SNY
Sanofi
$53.95Bn
44.24
-0.20%
-11.32%
Sanofi is a global pharmaceutical company that discovers, develops, and markets branded prescription drugs across multiple therapeutic areas. Its revenue is primarily derived from the sale of branded medicines such as Dupixent for immunology and Sarclisa for oncology.
EW
Edwards Lifesciences
$51.83Bn
89.89
+0.12%
+10.67%
Edwards Lifesciences designs and manufactures therapeutic and surgical medical devices, specifically heart valves. Its revenue is driven by the sale of the SAPIEN family of transcatheter valves, the PASCAL and EVOQUE repair/replacement systems, and surgical tissue valves like INSPIRIS RESILIA.
BDX
Becton Dickinson
$50.32Bn
184.73
-1.55%
-3.41%
BD's Medical Essentials segment produces a vast array of consumables and disposables, including peripheral intravenous catheters, safety hypodermic syringes, needles, and sharps disposal systems. These products represent a core part of their revenue stream and match the description of medical supplies and consumables.
HUM
Humana
$48.21Bn
401.46
-1.29%
+28.68%
Humana's primary revenue is generated from insurance premiums through its Insurance segment, which offers Medicare Advantage plans, Medicare Part D, and state-based Medicaid contracts. The company is explicitly described as one of the largest providers of Medicare Advantage plans and competes with other managed care organizations.
MDLN
Medline
$48.11Bn
36.59
+0.00%
—
Medline manufactures and sells a vast array of medical supplies and consumables, including wound care, exam gloves, protective apparel, and surgical procedure trays. These products are sold to hospitals, surgery centers, and physician offices as their core business.
NTRA
Natera
$47.13Bn
328.18
+0.16%
+95.89%
Natera operates as a diagnostics company that provides clinical laboratory and genetic testing services, generating the vast majority of its revenue from processing millions of tests. Its business model involves performing molecular and bioinformatics analysis on patient samples for oncology, women's health, and organ health, billing for these diagnostic-testing services.
RVMD
Revolution Medicines
$45.00Bn
210.02
-0.40%
+428.09%
Revolution Medicines is a clinical-stage company developing small-molecule RAS(ON) inhibitors for cancers such as pancreatic ductal adenocarcinoma and non-small cell lung cancer. Its core business is the discovery and development of branded prescription pharmaceuticals based on its proprietary tri complex technology platform.
SLF
2nd
Sun Life Financial
$44.85Bn
80.99
+0.26%
+39.57%
The company provides group benefits and health solutions, including health and disability insurance and stop-loss products, which function as managed-care and health insurance plans for employers and individuals.
IQV
Iqvia Holdings
$44.06Bn
267.67
-1.47%
+45.41%
IQVIA operates a 'Research & Development Solutions' segment that provides outsourced clinical research and clinical trial related services to biopharmaceutical customers. This matches the description of a Contract Research Organization (CRO) that runs clinical development for drug and device sponsors.
A
Agilent Technologies
$42.55Bn
150.90
+0.65%
+20.51%
Agilent designs and manufactures life-sciences research tools and instruments, including liquid chromatography, gas chromatography, and mass spectrometry systems. These products are sold to pharmaceutical, biotechnology, and academic research institutions for drug discovery and chemical analysis.
TEVA
Teva Pharmaceutical Industries
$42.34Bn
36.33
-0.76%
+96.59%
Teva is described as a biopharmaceutical company with a strong generics business, ranking among the top three global suppliers of generic prescription drugs. Its revenue is primarily driven by a broad generic portfolio including oral solids, injectables, and inhalants marketed to wholesalers and pharmacies.
IDXX
Idexx Laboratories
$42.23Bn
535.38
+1.15%
-16.40%
The company's primary business is focused on the animal health market, providing diagnostic products and services for companion animals, livestock, poultry, and dairy. Key products include the IDEXX VetLab suite, Catalyst One Chemistry analyzer, and tests for Bovine Viral Diarrhea Virus.
ONC
BeOne Medicines
$40.49Bn
358.26
-1.22%
+6.54%
BeOne Medicines discovers, develops, and markets branded prescription drugs for oncology, specifically hematology and solid tumors. Its primary revenue is derived from the sales of branded medicines such as BRUKINSA and TEVIMBRA.
WAT
Waters
$40.23Bn
409.52
-1.01%
+36.65%
Waters Corporation designs and manufactures analytical instruments, including HPLC, UPLC, and mass spectrometry systems, as well as chromatography columns and reagents. These products are sold as tools for life-sciences research and bioproduction to customers in pharmaceuticals, biotechnology, and academic research.
ALNY
Alnylam Pharmaceuticals
$35.59Bn
266.11
+0.61%
-40.52%
Alnylam is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically RNAi therapeutics consisting of small interfering RNA (siRNA). Its revenue is generated from the sale of biologic products such as AMVUTTRA, ONPATTRO, and GIVLAARI, as well as collaboration payments and royalties from partners like Novartis and Sanofi.
ALC
Alcon
$34.36Bn
70.50
-2.18%
-10.44%
Alcon's primary business involves the design and manufacture of therapeutic and surgical medical devices, specifically intraocular lenses (IOLs), phacoemulsification systems, and 3D visualization platforms for cataract and glaucoma surgeries.
DXCM
Dexcom
$33.17Bn
87.90
-2.02%
+11.38%
Dexcom designs and manufactures continuous glucose monitoring (CGM) systems, including the G7 and Stelo, which are wearable medical devices used for diabetes and metabolic health management. Revenue is primarily generated from the sale of this hardware, including sensors, transmitters, and receivers.
CNC
Centene
$33.12Bn
67.04
-1.47%
+123.02%
Centene is a managed care company that generates the vast majority of its revenue from premium payments for Medicaid, Medicare, and Commercial health insurance plans. It operates as a health insurer for low-income families, seniors, and individuals through the Ambetter Health brand and government contracts.
ILMN
Illumina
$32.95Bn
218.22
-1.55%
+127.15%
Illumina designs and manufactures sequencing and array-based instruments, reagents, and library preparation kits used for genomics and proteomics research. Its primary revenue comes from selling these life-sciences research tools and consumables to research institutions, academic centers, and biotechnology companies.
RMD
Resmed
$32.94Bn
228.36
-0.32%
-15.17%
ResMed designs and manufactures therapeutic medical devices for sleep apnea and respiratory disorders, specifically CPAP, APAP, bilevel, and high flow therapy systems. These are regulated treatment devices sold to patients, hospitals, and home medical equipment providers.
BIIB
Biogen
$32.63Bn
220.83
-1.64%
+57.80%
Biogen is a biopharmaceutical company that researches and commercializes therapies derived from biological science, such as monoclonal antibodies and recombinant proteins. Its revenue is driven by biologic products like SPINRAZA for spinal muscular atrophy and LEQEMBI for Alzheimer's disease.
ZTS
Zoetis
$31.39Bn
75.80
-0.59%
-50.27%
Zoetis is a global leader in animal health, developing and selling medicines, vaccines, and parasiticides for companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, fish, sheep). Its revenue is primarily generated from the sale of these animal-health products to veterinarians, pet owners, and livestock producers.
GEHC
GE HealthCare Technologies
$31.10Bn
68.86
-1.23%
-4.86%
The company's largest segments, Imaging and Advanced Visualization Solutions, focus on manufacturing clinical diagnostic equipment such as CT, MRI, X-ray, and Ultrasound systems. These products are sold to hospitals and health systems for the purpose of clinical diagnosis.
IR
2nd
Ingersoll Rand
$29.62Bn
76.34
+1.25%
-3.61%
The Precision and Science Technologies segment designs and manufactures life science tools and single-use powder and liquid handling containment solutions for life science and medical applications.
MTD
2nd
Mettler Toledo International
$29.15Bn
1,344.10
-0.89%
+5.95%
Mettler-Toledo designs and manufactures laboratory instruments, including balances, pipettes, and analyzers, which contribute approximately 56% of net sales and are used in life sciences research and development.
INSM
Insmed
$27.57Bn
126.29
-0.31%
-11.99%
Insmed is a biopharmaceutical company that develops therapies derived from biological science, including the monoclonal antibody INS1148 and the Pulmovance liposomal platform used for ARIKAYCE. Its revenue is derived from the sale of these biologic-based products and potential milestone payments.
LH
Labcorp Holdings
$26.44Bn
326.86
-1.40%
+19.36%
Labcorp's Diagnostics Laboratories segment performs over 750 million tests annually, providing clinical, genetic, and anatomic pathology services to physicians, hospitals, and patients. This core activity of running tests on patient samples and billing payers per test aligns directly with the Diagnostic Labs classification.
BNTX
BioNTech SE
$26.24Bn
103.76
+0.86%
+0.25%
BioNTech is a biotechnology company that researches and commercializes therapies derived from biological science, specifically leveraging messenger RNA (mRNA) technology and protein-based therapeutics. Its revenue is derived from the sale of the mRNA-based COVID-19 vaccine Comirnaty and significant collaboration and milestone payments from partners like Pfizer and Bristol Myers Squibb.
DGX
Quest Diagnostics
$26.16Bn
237.03
-0.95%
+32.04%
Quest Diagnostics provides clinical laboratory and diagnostic testing services, generating revenue primarily from fees charged for laboratory testing. The company offers a broad menu of routine and specialty tests in areas such as cardiology, oncology, and genetics.
INCY
Incyte
$25.47Bn
126.75
-0.98%
+45.76%
Incyte is a biopharmaceutical company that discovers, develops, and markets branded prescription drugs such as JAKAFI, ICLUSIG, and OPZELURA. Its revenue is primarily derived from the sale of these branded pharmaceutical products to specialty pharmacies, hospital pharmacies, and wholesalers.
ROIV
Roivant Sciences
$25.24Bn
34.93
+1.51%
+177.44%
Roivant is a biopharmaceutical company that develops therapies derived from biological science, specifically monoclonal antibodies like IMVT 1402 and batoclimab. Its revenue model is based on biologic product development, collaboration milestones, and royalties from partners such as HanAll and Bayer.
WST
West Pharmaceutical Services
$23.93Bn
339.92
-0.76%
+36.54%
The company's primary business is the manufacture of primary proprietary packaging solutions for injectable drugs, specifically elastomer-based containment components such as stoppers, seals, plungers, and cartridge components. These are medical supplies and consumables sold to pharmaceutical and biologic companies for use in their injectable formulations.
IFF
2nd
International Flavors & Fragrances
$22.04Bn
86.32
-0.19%
+31.73%
The Health & Biosciences segment produces biotechnology-derived enzymes, probiotics, and specialty ingredients sold to the pharmaceutical and health industries. These are functional ingredients manufactured for use in other companies' finished medical or health products.
STE
Steris
$21.90Bn
224.63
-0.83%
-7.71%
STERIS manufactures capital equipment for healthcare providers, including sterilizers, surgical tables, and automated endoscope reprocessors. These are therapeutic and surgical medical devices used in operating rooms and procedural centers.
GH
Guardant Health
$21.57Bn
161.41
+0.23%
+148.09%
Guardant Health operates clinical laboratories and generates revenue primarily from providing diagnostic testing services, such as the Guardant360 CDx and Shield tests, to healthcare providers and hospitals. The company bills payers and patients for these clinical laboratory services.
THC
Tenet Healthcare
$21.33Bn
264.85
+0.51%
+41.70%
Tenet Healthcare operates 50 acute care and specialty hospitals providing inpatient services such as emergency care, intensive care, and specialized treatments in cardiology and neurosciences. Revenue is generated from hospital admissions and surgical procedures reimbursed by Medicare, Medicaid, and commercial insurers.
UTHR
United Therapeutics
$20.81Bn
487.61
-0.54%
+24.57%
The company's primary revenue is derived from the sale of branded prescription pharmaceuticals for pulmonary hypertension and oncology, specifically Tyvaso DPI, Remodulin, Orenitram, and Unituxin.
EXAS
Exact Sciences
$20.02Bn
104.91
+0.95%
+136.92%
Exact Sciences provides clinical diagnostic and laboratory testing services, specifically for cancer screening and precision oncology. The company generates revenue by delivering test results for products like Cologuard Plus, Cancerguard, and Oncotype DX to patients and healthcare providers.
VTRS
Viatris
$19.39Bn
16.88
-0.35%
+60.00%
Viatris is described as one of the largest providers of generic medicines globally, generating significant revenue from simple and complex generics, biosimilars, and specialty generics. The profile explicitly highlights its position as a major player in the generic drug market competing with Teva and Sandoz.
ZBH
Zimmer Biomet Holdings
$18.70Bn
98.06
-0.88%
-6.65%
Zimmer Biomet designs and manufactures therapeutic and surgical medical devices, specifically orthopedic reconstructive implants, knee and hip replacement systems, and thoracic devices. These products are sold to orthopedic surgeons, neurosurgeons, and hospitals for use in surgical procedures.
NDSN
2nd
Nordson
$17.73Bn
318.36
+0.27%
+40.86%
The Medical Interventional Solutions business provides therapeutic and surgical medical devices, including interventional delivery systems, balloons, and cardiovascular cannula for minimally invasive surgical procedures.
FTV
2nd
Fortive
$17.23Bn
56.94
-1.11%
+19.67%
The Advanced Healthcare Solutions segment designs and manufactures therapeutic and surgical medical devices, including instrument sterilization systems and radiation detection and safety monitoring tools under brands like ASP and Landauer.
ASND
Ascendis Pharma A
$16.77Bn
270.56
-0.21%
+35.27%
Ascendis Pharma is a biopharmaceutical company that uses its proprietary TransCon technology platform to develop therapies derived from biological science, such as SKYTROFA for growth hormone deficiency. Its revenue is generated from the sale of these biologic products and through collaboration milestone payments and royalties.
LDOS
2nd
Leidos Holdings
$16.70Bn
133.10
+0.55%
-25.10%
Through its managed health services, the company deploys a national footprint of health clinics and providers to conduct medical, disability, and behavioral health examinations for the Department of Veterans Affairs.
MEDP
Medpace Holdings
$16.50Bn
591.29
-0.35%
+22.87%
Medpace is a global contract research organization (CRO) that provides outsourced clinical development services, including study design, site management, patient recruitment, and regulatory submissions. It earns fee-for-service revenue from biotechnology, pharmaceutical, and medical device sponsors for Phase I through IV clinical trials.
IEX
2nd
Idex
$16.49Bn
223.67
+0.22%
+35.67%
The Health & Science Technologies segment specifically produces biocompatible medical devices and implantables sold to medical device makers.
JAZZ
Jazz Pharmaceuticals
$16.02Bn
246.81
-0.31%
+92.79%
Jazz Pharmaceuticals develops and markets branded prescription drugs for rare diseases, including Xywav for sleep disorders, Epidiolex for epilepsies, and Zepzelca for oncology. Its revenue is primarily generated through net product sales of these specialized, branded medications.
NBIX
Neurocrine Biosciences
$15.81Bn
155.64
-1.71%
+14.35%
Neurocrine Biosciences develops and markets branded prescription drugs, with the vast majority of its revenue coming from the sale of INGREZZA for tardive dyskinesia and CRENESSITY for congenital adrenal hyperplasia. These are branded small-molecule pharmaceuticals sold through specialty pharmacies and wholesale distributors.
MDGL
Madrigal Pharmaceuticals
$15.77Bn
541.08
-0.28%
+24.31%
Madrigal Pharmaceuticals is a biopharmaceutical company that developed Rezdiffra (resmetirom), a thyroid hormone receptor beta agonist, and maintains a pipeline of biologics including GLP-1 receptor agonists and siRNA programs. Its revenue is derived from the sale of these biology-based therapies for the treatment of MASH.
SOLV
Solventum
$15.60Bn
91.69
-0.82%
+26.68%
Solventum's MedSurg segment sells therapeutic and surgical medical devices, including negative pressure wound therapy and surgical supplies. These products are designed to accelerate healing and mitigate patient risk during surgical operations.
EXEL
Exelixis
$14.69Bn
59.01
-0.20%
+59.66%
Exelixis focuses on the discovery, development, and commercialization of branded prescription oncology medicines, specifically small molecule tyrosine kinase inhibitors. Its primary revenue is generated from the net product sales of branded drugs such as CABOMETYX and COMETRIQ.
BBIO
BridgeBio Pharma
$14.62Bn
74.84
-0.76%
+44.37%
BridgeBio is a biopharmaceutical company that develops therapies derived from biological science to treat genetic diseases, such as acoramidis for ATTR-CM and infigratinib for achondroplasia. Its revenue model includes net product sales of Attruby, as well as milestone payments and royalties from collaborations with Bayer and Alexion.
RVTY
Revvity
$14.53Bn
130.24
-0.28%
+56.24%
Revvity's Life Sciences segment sells a comprehensive portfolio of research tools, including radiometric detection reagents, microscopy imaging reagents, recombinant cell lines, and automated liquid handling platforms to pharmaceutical, biotech, and academic researchers.
BWXT
2nd
BWX Technologies
$14.44Bn
157.56
-1.70%
-2.11%
The company produces and sells radiopharmaceuticals and medical radioisotopes to hospitals and pharmaceutical firms for diagnostic and therapeutic applications.
SMMT
Summit Therapeutics
$13.96Bn
17.60
+2.74%
-26.05%
Summit Therapeutics is a clinical-stage biopharmaceutical company developing ivonescimab, which is described as a bispecific antibody. Its revenue model is based on licensing agreements, milestone payments, and royalties, which is characteristic of biotechnology developers.
CRL
Charles River Laboratories International
$13.77Bn
288.60
-1.56%
+77.79%
The company is a leading provider of non-clinical drug development services, specifically offering outsourced drug discovery, target identification, lead optimization, and regulated safety assessment services like toxicology and pathology. These activities are performed for pharmaceutical and biotechnology sponsors as fee-for-service contracts.
COO
Cooper Companies
$13.56Bn
69.59
-1.49%
+3.65%
The company designs and manufactures therapeutic and surgical medical devices, including soft contact lenses (CooperVision) and surgical devices for gynecologic procedures and contraceptive products like Paragard (CooperSurgical). These products are sold to eye care practitioners, hospitals, and ambulatory surgery centers.
BAX
Baxter International
$13.34Bn
25.80
+0.94%
+9.60%
Baxter's core business involves the manufacture of medical supplies and consumables, specifically sterile intravenous (IV) solutions, infusion systems, administration sets, and parenteral nutrition therapies. These products are sold as disposables and consumables to hospitals and healthcare providers.
BMRN
Biomarin Pharmaceutical
$12.88Bn
66.53
+0.15%
+12.80%
BioMarin is a biotechnology company that develops and commercializes therapies derived from biological science, specifically enzyme replacement therapies like VIMIZIM and NAGLAZYME for lysosomal storage disorders. Its revenue is driven by the sale of these biologic products and its focus on genetic medicine.
PEN
Penumbra
$12.69Bn
322.18
+0.27%
+19.45%
Penumbra designs and manufactures therapeutic and surgical medical devices, specifically for vascular and neurovascular conditions. Its product portfolio includes the INDIGO system for thrombectomy and the RUBY embolization platform, which are used by physicians in hospitals to remove blood clots and treat aneurysms.
ICLR
Icon
$12.62Bn
164.85
+0.78%
-8.42%
ICON is explicitly described as a leading global contract research organization (CRO) that provides outsourced development services, including trial design, execution, and management of Phase I-IV clinical studies for pharmaceutical and biotechnology sponsors.
HALO
Halozyme Therapeutics
$12.57Bn
110.19
-0.51%
+50.12%
Halozyme is a biopharmaceutical company that develops therapies and delivery platforms derived from biological science, specifically using recombinant human hyaluronidase (rHuPH20). Its revenue model is based on biologic product sales, licensing fees, milestone payments, and royalties from partners like Roche and Pfizer.
ELAN
Elanco Animal Health
$12.21Bn
24.45
+0.12%
+39.95%
Elanco develops, manufactures, and markets a diverse portfolio of animal health products, including parasiticides, vaccines, and pain therapeutics for both companion animals and livestock. Its revenue is derived from the sale of these veterinary pharmaceuticals and nutritional products to farmers, pet owners, and veterinarians.
ARWR
Arrowhead Pharmaceuticals
$12.19Bn
86.34
-0.17%
+208.36%
Arrowhead Pharmaceuticals researches and commercializes therapies derived from biological science, specifically using RNA interference (RNAi) and siRNA triggers to silence genes. Its revenue is generated from the sale of its biologic product REDEMPLO and through collaboration payments and royalties from partners like Amgen and Takeda.
KNSA
Kiniksa Pharmaceuticals International
$12.15Bn
77.91
-3.18%
+119.59%
Kiniksa is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically monoclonal antibodies and cytokine traps like ARCALYST. Its revenue is derived from the sale of these biologic products, as well as milestone payments and royalties from licensing partnerships.
CORT
Corcept Therapeutics
$12.07Bn
111.62
-1.05%
+56.46%
Corcept Therapeutics discovers, develops, and markets branded prescription drugs, specifically its lead product Korlym for the treatment of hypercortisolism. Its revenue is generated from the sale of these branded pharmaceuticals to physicians and healthcare providers.
EHC
Encompass Health
$12.02Bn
121.84
-0.68%
-2.12%
Encompass Health is the largest owner and operator of inpatient rehabilitation hospitals, operating 173 facilities with 11,465 licensed beds. Its revenue is primarily derived from facility-based inpatient care reimbursed by Medicare, Medicaid, and private insurers.
BTSG
BrightSpring Health Services
$11.99Bn
60.73
-1.14%
+152.10%
BrightSpring delivers care in the home and residential settings, specifically providing home health, hospice, rehabilitation therapy, and personal care services. The profile explicitly states that it serves patients in their own homes, senior living communities, and skilled nursing facilities.
DVA
Davita
$11.76Bn
183.92
+1.24%
+35.27%
DaVita primarily operates a vast network of freestanding outpatient dialysis centers and provides physician practice management and specialty care for patients with end-stage renal disease. Its core revenue is generated from per-procedure dialysis treatments delivered in these outpatient clinic settings.
TEM
Tempus AI
$11.32Bn
64.62
-0.06%
-17.28%
Tempus AI operates a laboratory network that performs genomic and molecular testing, including next-generation sequencing and PCR, for oncology and cardiology patients. It generates primary revenue by providing these diagnostic testing services to hospitals, physicians, and other healthcare providers.
TECH
Bio-Techne
$11.31Bn
72.43
-0.03%
+36.87%
Bio-Techne's Protein Sciences segment sells high-quality biological reagents such as cytokines, growth factors, and antibodies, as well as proteomic analytical tools like western blot systems and multiplexed ELISA platforms for life science research and drug discovery.
ALGN
Align Technology
$11.30Bn
158.63
-0.76%
+17.77%
Align Technology's primary business is the design and manufacture of clear aligners (Invisalign) and intraoral scanners (iTero) specifically for orthodontists and dental practitioners. The company's core revenue is derived from dental-specific products and services, fitting the definition of the Dental industry.
AXSM
Axsome Therapeutics
$10.81Bn
206.68
-0.80%
+66.13%
Axsome is a fully integrated biopharmaceutical company that manufactures and markets branded prescription drugs, including AUVELITY for major depressive disorder, SUNOSI for excessive daytime sleepiness, and SYMBRAVO for migraine. Its core revenue stream comes from the sale of these branded pharmaceutical products in the United States.
KRYS
Krystal Biotech
$10.60Bn
358.24
-3.56%
+138.51%
Krystal Biotech focuses on the discovery and commercialization of genetic medicines using a patented HSV1-based gene therapy platform. Its lead product, VYJUVEK, is a corrective gene therapy for dystrophic epidermolysis bullosa, and its pipeline includes inhaled and ophthalmic gene therapies.
MOG-A
2nd
Moog
$10.57Bn
371.61
+0.32%
+92.81%
Moog manufactures medical devices and components, specifically pumps and sets for enteral clinical nutrition and infusion therapy, as well as components for surgical handpieces.
DCI
2nd
Donaldson
$10.55Bn
91.03
+0.56%
+14.33%
The Life Sciences segment sells bioprocessing equipment such as bioreactors and fermenters, as well as consumables including chromatography devices and reagents used for cell growth, separation, and purification.
GMED
Globus Medical
$10.51Bn
78.26
+0.20%
+33.10%
Globus Medical designs and manufactures therapeutic and surgical medical devices, specifically implantable devices for spinal, orthopedic, and neurosurgical procedures such as pedicle screw systems and interbody spacers. It also sells spinal cord stimulation systems and robotics platforms like ExcelsiusGPS for surgical guidance.
GKOS
Glaukos
$10.46Bn
177.67
-1.52%
+88.07%
Glaukos generates the majority of its revenue from the sale of medical devices, specifically the iStent family of micro scale surgical devices used in Micro Invasive Glaucoma Surgery (MIGS). These products are sold directly to ambulatory surgery centers, hospitals, and physician private practices.
MOH
Molina Healthcare
$10.45Bn
200.95
-1.00%
+13.51%
Molina Healthcare operates as a managed care organization providing health insurance plans for Medicaid, Medicare, and the Affordable Care Act Marketplace. Its primary revenue is generated from per-member-per-month premium payments received for managing care for these populations.
BIO
Bio-Rad Laboratories
$10.34Bn
386.54
-0.34%
+34.19%
Bio-Rad's Life Science segment develops and markets instruments, systems, reagents, and consumables used to separate, purify, and quantify biological materials for research and biopharmaceutical manufacturing. These products are sold to universities, medical schools, and biotechnology companies for use in laboratory environments.
PODD
Insulet
$10.23Bn
147.48
-2.06%
-57.07%
Insulet designs and manufactures the Omnipod platform, which consists of tubeless insulin delivery pods and controllers used for the treatment of insulin-dependent diabetes. These are therapeutic medical devices sold to wholesalers, distributors, and consumers.
APGE
Apogee Therapeutics
$10.18Bn
135.07
-0.01%
+256.76%
Apogee Therapeutics is a clinical-stage biotechnology company developing biologics, specifically antibody programs targeting IL-13, OX40L, TSLP, and IL-4Rα. Its product candidates, such as APG777 and APG279, are derived from biological science and advanced antibody engineering.
GPCR
Structure Therapeutics
$10.11Bn
47.34
+0.00%
+140.18%
Structure Therapeutics is a biopharmaceutical company focused on discovering and developing oral small molecule therapeutics, such as aleniglipron (a GLP1R agonist) and amylin receptor agonists. Because its pipeline consists of small-molecule drugs rather than biologics, it fits the Pharmaceuticals classification.
CYTK
Cytokinetics
$10.11Bn
72.72
-1.66%
+45.47%
Cytokinetics develops and markets branded prescription drugs, specifically the oral small molecule inhibitor MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy. Its revenue is generated from the sales of these branded pharmaceuticals and associated licensing milestones.
HSIC
Henry Schein
$10.05Bn
89.81
-1.16%
+33.79%
The company's primary revenue driver is the Global Distribution and Value Added Services segment (84.5% of sales), which distributes national and corporate brand merchandise, equipment, and pharmaceuticals to dental and medical practitioners.
RDY
Dr Reddys Laboratories
$9.99Bn
11.97
-0.50%
-15.41%
The company's Global Generics segment contributes the majority of its income through the manufacturing and marketing of generic equivalents and biosimilar alternatives to reference drugs. It is explicitly described as one of the world's leading generic pharmaceutical companies.
ENSG
Ensign
$9.95Bn
170.79
-0.76%
-0.50%
The company generates approximately 95.6% of its revenue from the operation of skilled nursing facilities, providing short and long-term nursing care for the elderly and patients with chronic conditions. It also operates senior living units providing residential accommodations and assistance in activities of daily living.
PRAX
Praxis Precision Medicines
$9.82Bn
351.81
-0.94%
+655.77%
Praxis is a clinical-stage biopharmaceutical company that develops therapies derived from biological science, specifically antisense oligonucleotides (ASOs) via its Solidus platform. Its revenue model relies on collaboration, milestone payments, and royalties, which is characteristic of biotechnology developers.
NUVL
Nuvalent
$9.75Bn
123.96
+0.00%
+50.33%
Nuvalent is a biopharmaceutical company developing small molecule inhibitors, such as zidesamtinib (NVL-520) and neladalkib (NVL-655), which are branded prescription drug candidates. Its core business is the discovery and development of small-molecule pharmaceuticals for oncology.
KYMR
Kymera Therapeutics
$9.72Bn
117.39
+0.09%
+171.11%
Kymera Therapeutics develops oral small molecule medicines, such as those targeting STAT6, IRF5, IRAK4, and CDK2, which are branded prescription pharmaceuticals. The company's core business is the discovery and development of these small-molecule drugs to treat immune inflammatory diseases and oncology.
CHWY
2nd
Chewy
$9.70Bn
23.67
-1.21%
-41.91%
The company operates Chewy Pharmacy, which dispenses veterinarian-prescribed medications and compounded formulations, and provides in-person veterinary services through its Chewy Vet Care clinic network.
IONS
Ionis Pharmaceuticals
$9.62Bn
58.09
-0.07%
-2.12%
Ionis is a biotechnology company that develops RNA-targeted medicines using proprietary antisense technology to modify gene expression. Its revenue is derived from the sale of biologic-based products like SPINRAZA and QALSODY, as well as royalties and milestone payments from collaborations.
RGEN
Repligen
$9.46Bn
167.60
-1.19%
+38.99%
Repligen provides bioprocessing technologies, instruments, and consumables used in the manufacturing of biological drugs, such as XCell ATF cell retention systems and OPUS PrePacked Columns. Its revenue is generated from the sale of these life-sciences research and bioproduction tools to biopharmaceutical companies and CDMOs.
PTGX
Protagonist Therapeutics
$9.42Bn
145.72
-2.07%
+150.77%
Protagonist Therapeutics is a biotechnology company that researches and develops peptide-based therapeutics, including oral and injectable peptides for inflammatory, immunologic, and metabolic diseases. Its revenue model consists of collaboration agreements, upfront payments, and milestone payments from partners like Janssen Biotech and Takeda Pharmaceuticals.
ABVX
Abivax
$9.02Bn
114.79
+0.66%
+37.23%
Abivax is a clinical-stage biotechnology company focused on discovering and developing therapeutics for chronic inflammatory diseases, specifically ulcerative colitis and Crohn's disease. Its revenue currently comes from research collaborations, licensing agreements, and grant funding, which is characteristic of the H-02 biotechnology classification.
CRNX
Crinetics Pharmaceuticals
$8.99Bn
84.95
+0.00%
+155.11%
Crinetics Pharmaceuticals discovers, develops, and markets branded prescription drugs, specifically small-molecule oral agents like PALSONIFY (paltusotine) for acromegaly. Its revenue is generated from the sales of these branded pharmaceutical products and milestone payments from licensing agreements.
BRKR
Bruker
$8.91Bn
58.50
-1.53%
+96.37%
Bruker's core business is the development and manufacture of high-performance scientific instruments for life sciences research, including mass spectrometry (timsTOF), nuclear magnetic resonance (NMR) systems, and spatial biology platforms (CosMx). These tools are sold to academic, government, pharmaceutical, and biotechnology customers for molecular and cellular research.
PCVX
Vaxcyte
$8.86Bn
61.16
-0.02%
+90.53%
Vaxcyte is a clinical-stage biotechnology company developing vaccines using its XpressCF cell-free protein synthesis platform to produce complex antigens. Its revenue model currently consists of research grants, collaboration funding, and potential milestone payments and royalties, which is characteristic of H-02.
OSCR
Oscar Health
$8.81Bn
32.24
+0.06%
+75.41%
Oscar's primary revenue is generated from health insurance policy premiums collected from the Centers for Medicare & Medicaid Services and directly from members. The company operates as a health insurer offering individual and family plans under the Affordable Care Act, managing insurance risk and medical loss ratios.
UHS
Universal Health Services
$8.77Bn
169.61
+0.33%
-8.65%
Universal Health Services owns and operates 375 inpatient facilities, including 29 inpatient acute care hospitals and a surgical hospital. Revenue is generated from facility-based inpatient and surgical care reimbursed by Medicare, Medicaid, and commercial payers.
TGTX
Tg Therapeutics
$8.57Bn
55.99
-1.27%
+76.57%
TG Therapeutics is a biotechnology company that commercializes BRIUMVI, an anti-CD20 monoclonal antibody, and develops other biologics. Its revenue is derived from the sale of this biologic product and milestone payments from collaborations.
IBRX
ImmunityBio
$8.51Bn
8.08
-1.34%
+240.93%
ImmunityBio is a biotechnology company that develops and commercializes therapies derived from biological science, specifically its lead biologic product ANKTIVA, an IL-15 receptor superagonist. The company generates revenue from the commercial sale of this biologic product for the treatment of BCG-unresponsive NMIBC CIS.
TXG
10x Genomics
$8.16Bn
62.65
-0.90%
+361.68%
10x Genomics develops and sells instruments and consumables for life-sciences research, specifically the Chromium single cell platform and Visium and Xenium spatial platforms. Its customers include academic research institutions, government laboratories, and biotechnology firms using these tools for biological analysis.
ATR
2nd
Aptargroup
$8.10Bn
127.40
-0.62%
-5.78%
The company's Pharma segment produces therapeutic delivery devices, including nasal drug delivery spray pumps, metered dose inhaler valves, and digital health solutions for oncology and neurology.
IMVT
Immunovant
$8.10Bn
39.25
+0.33%
+143.49%
Immunovant is a clinical-stage biotechnology company developing therapies derived from biological science, specifically fully human monoclonal antibodies (IMVT-1402 and batoclimab). Its core business is the research and development of these biologics to treat autoimmune diseases.
SYRE
Spyre Therapeutics
$7.84Bn
88.98
+1.98%
+429.33%
Spyre Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically monoclonal antibodies targeting α4β7, TL1A, and IL23. Its revenue model currently relies on collaboration and licensing arrangements, such as those with Paragon, which include milestone payments and royalties.
TWST
Twist Bioscience
$7.82Bn
124.72
-3.10%
+379.69%
Twist Bioscience manufactures and sells synthetic genes, oligonucleotides, and next-generation sequencing tools (such as target enrichment probes and library preparation kits) used for research and bioproduction. These products are sold to biotech, pharma, and academic laboratories for applications like drug discovery and basic biological investigation.
ALKS
Alkermes
$7.72Bn
46.10
-1.66%
+53.67%
Alkermes develops and markets branded prescription drugs for neuroscience disorders, including ARISTADA, LYBALVI, VIVITROL, and LUMRYZ. Its primary revenue is generated through the direct sales of these proprietary branded pharmaceuticals.
OKLO
2nd
Oklo
$7.64Bn
41.28
+3.59%
-42.85%
Through its subsidiary Atomic Alchemy, the company produces and sells radioisotopes for medical research and other applications, which falls under the manufacture of clinical diagnostic and medical-grade isotopes.
BLTE
Belite Bio
$7.62Bn
193.61
+13.16%
+204.85%
Belite Bio is a clinical-stage company developing branded prescription drugs, specifically oral small molecules like tinlarebant (LBS 008) and LBS 009. These candidates target therapeutic areas such as Stargardt disease, geographic atrophy, and metabolic disorders like type 2 diabetes.
HNGE
Hinge Health
$7.41Bn
92.45
+1.79%
+60.95%
Hinge Health delivers clinical musculoskeletal care and prescriptions remotely via a virtual care team of licensed physical therapists, physicians, and health coaches. Its revenue is generated through subscription contracts with employers and health plans for access to this remote care platform.
CAI
Caris Life Sciences
$7.08Bn
25.07
-0.99%
-31.88%
Caris Life Sciences generates primary revenue from selling molecular profiling tests, including tissue and blood-based genomic profiling (MI Profile, Caris Assure), to physicians and hospitals. This activity constitutes providing clinical laboratory and diagnostic testing services for cancer detection and treatment monitoring.
RYTM
Rhythm Pharmaceuticals
$7.07Bn
102.74
-2.05%
+1.03%
Rhythm Pharmaceuticals is a biopharmaceutical company that develops therapies derived from biological science, specifically melanocortin-4 receptor agonists like setmelanotide (IMCIVREE). Its revenue is generated from the sale of these biologic products and through collaboration, milestone, and royalty payments from partners like Ipsen and LG Chem.
BLRX
BioLineRx
$6.97Bn
2.67
-0.74%
-26.45%
BioLineRx is a biopharmaceutical company that researches and develops therapies derived from biological science, such as motixafortide (a CXCR4 antagonist) for stem-cell mobilization and oncology. Its revenue model is based on biologic product licensing, milestone payments, and royalties from partners like Ayrmid and Gloria.
CHE
Chemed
$6.79Bn
519.51
-0.94%
+13.03%
The company operates VITAS, which provides hospice and palliative care services to elderly patients, with revenue primarily reimbursed by Medicare and Medicaid on a per diem basis.
SRRK
Scholar Rock Holding
$6.73Bn
55.33
-1.09%
+70.56%
Scholar Rock is a biopharmaceutical company that researches and develops therapies derived from biological science, specifically monoclonal antibodies like apitegromab and SRK 439. Its current revenue is derived from collaboration and milestone payments from partners such as Gilead, which is characteristic of clinical-stage biotechnology developers.
PACS
Pacs
$6.72Bn
42.46
-1.39%
+278.09%
PACS Group operates 321 post-acute care facilities providing skilled nursing care, assisted living, and independent living options. Its revenue is derived from Medicare, Medicaid, and private pay for services delivered in these residential settings.
CGON
CG Oncology
$6.59Bn
74.67
+0.46%
+141.34%
CG Oncology is a clinical-stage biopharmaceutical company developing cretostimogene grenadenorepvec, an oncolytic immunotherapy derived from biological science. Its current revenue is generated through collaboration and milestone payments from partners like Kissei Pharmaceutical and Lepu Biotech.
LNTH
Lantheus Holdings
$6.59Bn
100.97
-0.01%
+87.61%
Lantheus primarily generates revenue from the sale of diagnostic imaging agents such as PYLARIFY for prostate cancer PET imaging, DEFINITY for ultrasound enhancement, and Neuraceq for amyloid PET imaging. These products are sold to hospitals and independent imaging centers to facilitate clinical diagnosis.
MMED
MiniMed
$6.55Bn
23.28
-2.35%
—
MiniMed designs and manufactures therapeutic medical devices for diabetes management, specifically insulin pumps and smart pens. Its flagship product, the MiniMed 780G, is an automated insulin delivery system that combines pump technology with real-time glucose sensing.
MIRM
Mirum Pharmaceuticals
$6.53Bn
100.90
+0.27%
+35.24%
Mirum Pharmaceuticals is a biopharmaceutical company that researches and commercializes therapies for rare diseases, such as Livmarli and Cholbam. Its revenue is derived from the sale of these biologic-based or specialized medicines, as well as milestone payments and royalties from collaborative agreements.
HIMS
Hims & Hers Health
$6.47Bn
27.72
-0.36%
-42.38%
The company operates a consumer-first health platform providing telehealth consultations that connect patients with licensed healthcare professionals for prescriptions. Its revenue is primarily generated through subscription-based sales of medications and services delivered remotely via its digital platform.
BLCO
Bausch & Lomb
$6.45Bn
18.07
-0.44%
+23.85%
Bausch & Lomb manufactures a wide array of therapeutic and surgical medical devices, including intraocular lenses (enVista, Crystalens), phacoemulsification platforms (Stellaris Elite), and surgical instruments (Storz). These products are sold to hospitals, surgical centers, and eye care professionals.
STVN
Stevanato Group S.p.A
$6.21Bn
20.52
-0.24%
-10.94%
The company's primary revenue driver (88% from the Biopharmaceutical and Diagnostic Solutions segment) comes from the sale of drug containment products such as prefillable syringes, vials, cartridges, and ampoules, which are medical supplies and consumables.
TVTX
Travere Therapeutics
$6.15Bn
65.28
-1.89%
+208.65%
Travere Therapeutics develops and markets branded prescription drugs for rare kidney and metabolic diseases, such as FILSPARI (sparsentan) for IgAN and Thiola for cystinuria. Its revenue is primarily generated from the sales of these branded pharmaceutical products.
LQDA
Liquidia
$6.12Bn
68.66
+0.04%
+134.98%
Liquidia develops and markets branded prescription drugs for respiratory and vascular conditions, specifically its lead commercial product YUTREPIA. Revenue is primarily derived from the sale of this branded pharmaceutical to patients and healthcare providers.
COGT
Cogent Biosciences
$5.96Bn
34.76
-0.54%
+168.62%
Cogent Biosciences is a clinical-stage biotechnology company developing precision therapies derived from biological science, such as the tyrosine kinase inhibitor bezuclastinib. Its revenue model currently relies on licensing agreements, milestone payments, and potential future royalties from its lead assets.
TFX
Teleflex
$5.86Bn
138.22
-1.27%
+9.65%
Teleflex designs and manufactures therapeutic and surgical medical devices, including vascular catheters, interventional platforms like the MANTA Vascular Closure device, and surgical instruments such as bariatric staplers. These products are sold to hospitals and healthcare providers for use in critical care and surgical applications.
DBVT
DBV Technologies
$5.84Bn
13.47
-1.68%
+46.10%
DBV Technologies is a biopharmaceutical company developing therapies derived from biological science, specifically epicutaneous immunotherapy (EPIT) using the Viaskin patch for peanut and cow's milk allergies. Its revenue model currently relies on collaboration agreements, licensing, and milestone payments from partners like Nestlé Health Science.
ORKA
Oruka Therapeutics
$5.82Bn
92.51
+1.67%
+499.16%
Oruka Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, such as ORKA 001 and ORKA 002, which are biologics. Its revenue model is based on the future commercialization of these biological products and potential collaboration or licensing payments.
RDNT
RadNet
$5.80Bn
73.71
-1.22%
+3.89%
RadNet operates 418 freestanding outpatient imaging centers providing MRI, CT, PET, and X-ray exams. Revenue is generated from fees for these procedures paid by commercial insurers, Medicare, Medicaid, and patients.
XENE
Xenon Pharmaceuticals
$5.78Bn
59.75
-1.08%
+54.63%
Xenon Pharmaceuticals is a biopharmaceutical company focused on drug discovery and development of therapies for neurological and psychiatric disorders. Its revenue is currently generated through collaboration agreements, milestone payments, and potential royalties, specifically citing a license and collaboration agreement with Neurocrine Biosciences.
PTCT
Ptc Therapeutics
$5.77Bn
69.30
-2.94%
+24.75%
PTC Therapeutics is a biopharmaceutical company that develops and commercializes therapies derived from biological science for rare diseases. Its revenue is generated from the sale of biologic-based products such as Evrysdi for spinal muscular atrophy and Upstaza for aromatic L-amino decarboxylase deficiency.
AMRN
Amarin Corp Plc\Uk
$5.73Bn
13.63
-0.58%
-9.37%
Amarin is a pharmaceutical company that develops and markets branded prescription drugs, specifically its flagship product VASCEPA (icosapent ethyl). Its revenue is primarily generated from the sale of this branded pharmaceutical to wholesalers and through licensing agreements with commercial collaborators.
LGND
Ligand Pharmaceuticals
$5.69Bn
285.60
-1.43%
+70.26%
Ligand is a biopharmaceutical company that develops and licenses biological platform technologies like Captisol and NITRICIL. Its revenue is primarily derived from royalties on biologic products such as Kyprolis and Qarziba, as well as milestone payments from biotechnology development programs.
NOVT
2nd
Novanta
$5.61Bn
148.36
+0.76%
+31.77%
The company designs and manufactures therapeutic and surgical medical devices, specifically medical insufflators, endoscopic pumps, and integrated operating room technologies used in minimally invasive surgery.
AMRX
Amneal Pharmaceuticals
$5.57Bn
17.44
-2.41%
+82.81%
The company's primary revenue driver is its Affordable Medicines segment, which focuses on generic pharmaceuticals, injectables, and biosimilars, including first-to-file and first-to-market opportunities.
SHC
Sotera Health
$5.39Bn
18.90
-0.68%
+18.27%
The company operates Nelson Labs, which provides outsourced microbiological and analytical chemistry testing, as well as routine sterility and quality control testing for medical device and pharmaceutical customers.
CRSP
CRISPR Therapeutics AG
$5.39Bn
55.79
-1.24%
+5.78%
CRISPR Therapeutics focuses on developing therapies that modify genes and cells using CRISPR/Cas9 technology, such as CASGEVY for sickle cell disease. Its core business revolves around gene editing platforms, including in vivo gene editing and CAR T cell therapies.
MMSI
Merit Medical Systems
$5.35Bn
89.60
+1.16%
-0.54%
Merit Medical Systems designs and manufactures therapeutic and surgical medical devices, including stents, balloons, and delivery systems for cardiology, radiology, and endoscopy. Their core offerings include devices for vascular access, embolotherapy, and the EsophyX Z+ system for treating gastroesophageal reflux disease.
GRFS
Grifols
$5.31Bn
7.80
-1.02%
-18.67%
Grifols is a global producer of plasma derivatives, manufacturing biologic therapies such as immunoglobulins, albumin, and clotting factors (Factor VIII and IX). These are recombinant or plasma-derived proteins, which falls squarely under the biotechnology classification for therapies derived from biological science.
ERAS
Erasca
$5.06Bn
16.19
-0.43%
+1,032.17%
Erasca is a clinical-stage biotechnology company developing therapies derived from biological science, specifically mentioning a biparatopic antibody candidate (ERAS 12) and a modality agnostic strategy including large molecule antibodies. Its revenue model currently relies on licensing agreements, milestone payments, and collaborations typical of biotech developers.
RADX
Radiopharm Theranostics
$4.92Bn
2.08
-3.26%
-62.18%
Radiopharm Theranostics develops therapies derived from biological science, specifically using monoclonal antibodies, nanobodies, and peptides (e.g., Nano-mAbs and PSA-mAb segments). Its revenue model consists of collaboration payments, milestones, and royalties, which is characteristic of biotechnology developers.
ACAD
Acadia Pharmaceuticals
$4.82Bn
28.02
+0.57%
+8.94%
Acadia Pharmaceuticals develops and markets branded prescription drugs, specifically NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome. Its revenue is derived almost exclusively from the net product sales of these branded pharmaceuticals.
CELC
Celcuity
$4.68Bn
95.70
-0.76%
+76.57%
Celcuity is a clinical-stage biotechnology company developing gedatolisib, a targeted therapy for solid tumors. Its revenue model currently relies on collaboration payments and milestones from partners like Pfizer, which is characteristic of biology-based drug discovery and development.
HAE
Haemonetics
$4.68Bn
102.95
+0.13%
+90.37%
Haemonetics designs and manufactures therapeutic and surgical medical devices, including vascular closure, sensor-guided technologies, and esophageal protection product lines for hospital-based interventions. It also sells capital equipment for plasma and blood collection.
BLLN
BillionToOne
$4.65Bn
99.39
-0.11%
—
BillionToOne provides clinical molecular diagnostic testing services, specifically prenatal and oncology tests, and generates revenue from reimbursement by insurance, government programs, and patients. Its core business is performing these tests (e.g., UNITY suite and Northstar Select) on patient samples rather than selling the diagnostic machines themselves.
EWTX
Edgewise Therapeutics
$4.64Bn
43.07
+2.67%
+194.60%
Edgewise Therapeutics focuses on discovering and developing small molecule therapies, such as sevasemten and EDG-7500, for muscle diseases. Because its pipeline consists of small-molecule drug candidates rather than biologics, it fits the Pharmaceuticals classification.
DNTH
Dianthus Therapeutics
$4.63Bn
108.10
+0.23%
+345.59%
Dianthus Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically monoclonal antibodies like claseprubart and fusion proteins like DNTH212. Its revenue model consists of upfront payments, milestone payments, and royalties from collaboration agreements with partners such as Tenacia Biotechnology and Nanjing Leads Biolabs.
LIVN
LivaNova
$4.51Bn
81.92
+0.89%
+40.88%
LivaNova designs and manufactures therapeutic and surgical medical devices, specifically heart-lung machines, oxygenators, and the VNS Therapy System for epilepsy and depression. These products are sold to hospitals, neurosurgeons, and perfusionists for use in surgical and clinical treatment.
CON
Concentra Group Holdings Parent
$4.40Bn
34.47
+0.00%
+46.43%
Concentra operates a nationwide network of 628 stand-alone occupational health centers and 411 onsite health clinics providing outpatient care. Revenue is generated from per-visit services such as workers' compensation injury care, physical examinations, and drug screenings delivered in these clinic settings.
NVST
Envista Holdings
$4.38Bn
27.28
-1.12%
+34.38%
Envista Holdings is a global dental products company that designs and manufactures dental implants, orthodontic appliances (including Spark clear aligners), and restorative materials. Its primary customers are dental professionals, including orthodontists, periodontists, and general dentists.
ELVN
Enliven Therapeutics
$4.35Bn
59.32
-0.55%
+196.45%
Enliven Therapeutics is a clinical-stage company focused on the discovery and development of small molecule therapeutics, such as ELVN-001 for chronic myeloid leukemia and ELVN-002 for HER2 inhibition. These are branded prescription drug candidates rather than biologics, placing the company in the Pharmaceuticals category.
ITGR
Integer Holdings
$4.30Bn
126.46
+0.77%
+19.48%
Integer Holdings designs and manufactures therapeutic and surgical medical devices, including catheter-based systems, implantable pulse generators, and minimally invasive surgery tools. Its revenue is derived from selling these components and finished devices to multinational medical device original equipment manufacturers.
HTFL
Heartflow
$4.24Bn
48.91
-1.61%
+43.49%
Heartflow sells a diagnostic test (FFR CT Analysis and Plaque Analysis) that uses AI and 3D modeling to diagnose coronary artery disease. The company generates revenue on a pay-per-click basis when physicians review these diagnostic analyses, fitting the model of selling a diagnostic test rather than performing the scan itself.
DFTX
Definium Therapeutics
$4.22Bn
38.09
+0.24%
+320.42%
Definium Therapeutics is developing branded prescription drugs for brain health disorders, specifically DT120 (lysergide d tartrate) and DT402 (R enantiomer of MDMA). These are small-molecule pharmaceutical compounds targeting generalized anxiety disorder, major depressive disorder, and autism spectrum disorder.
ICUI
Icu Medical
$4.19Bn
167.58
+0.78%
+35.04%
ICU Medical designs and manufactures therapeutic and surgical medical devices, including large volume pumps, ambulatory infusion pumps, hemodynamic monitors, and anesthesia equipment. These products are sold to acute care hospitals and clinics for use in critical care and surgical procedures.
RLAY
Relay Therapeutics
$4.16Bn
19.04
+0.16%
+363.26%
Relay Therapeutics is a clinical-stage biotechnology company that uses its Dynamo platform to develop small molecule therapies for cancer and genetic diseases. Its revenue is currently derived from collaboration and milestone payments from partners like Genentech and Pfizer, which is characteristic of the H-02 classification.
MIR
2nd
Mirion Technologies
$4.14Bn
16.92
+0.89%
-18.10%
The company sells nuclear medicine products for patient dosing and medical diagnostics, as well as radiation therapy quality assurance hardware and software used in cancer centers.
INDV
Indivior Pharmaceuticals
$4.12Bn
34.94
+0.32%
+41.63%
Indivior develops and markets branded prescription pharmaceuticals, specifically SUBLOCADE and SUBOXONE Film, for the treatment of opioid use disorder. Its revenue is derived from the sale of these branded medications to healthcare providers, pharmacies, and distributors.
MANE
Veradermics
$4.11Bn
98.31
+0.57%
—
Veradermics is developing VDPHL01, an oral extended-release formulation of minoxidil, which is a branded prescription drug for pattern hair loss. The company intends to generate revenue from prescriptions written by dermatologists and primary care physicians.
VKTX
Viking Therapeutics
$4.07Bn
34.87
+2.62%
+29.97%
Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically dual agonists like VK2735 (GLP-1 and GIP receptors) and thyroid hormone receptor beta agonists like VK2809. Its revenue model currently consists of collaboration agreements, licensing arrangements, and research funding typical of biotechnology developers.
IRTC
iRhythm Holdings
$4.05Bn
123.07
-0.29%
-30.30%
iRhythm generates the majority of its revenue from providing ambulatory cardiac monitoring services through its own Medicare-enrolled independent diagnostic testing facilities. The company collects ECG data, processes it using proprietary software, and delivers diagnostic reports to physicians, billing third-party payers per monitoring episode.
TLX
Telix Pharmaceuticals
$4.04Bn
11.94
+1.70%
+27.56%
Telix is a biopharmaceutical company that develops and commercializes therapies and diagnostics derived from biological science, specifically antibody-based radiopharmaceuticals like Illuccix and Gozellix. Its core business involves the research and commercialization of biologic-based drug discovery for precision oncology.
DYN
Dyne Therapeutics
$4.02Bn
24.28
-2.69%
+80.12%
Dyne Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically using its FORCE platform to deliver oligonucleotides and enzymes. Its lead candidates, z-rostudirsen and z-basivarsen, are biologics targeting neuromuscular diseases like Duchenne muscular dystrophy and myotonic dystrophy type 1.
IOVA
Iovance Biotherapeutics
$3.98Bn
8.79
+1.03%
+299.55%
Iovance develops and commercializes tumor infiltrating lymphocyte (TIL) cell therapies, specifically its lead product Amtagvi (lifileucel), which is an individualized T cell therapy. The company's core platform is based on cellular modification to harness a patient's own immune system to destroy cancer cells.
LEGN
Legend Biotech
$3.97Bn
21.52
-1.06%
-38.50%
Legend Biotech focuses on the development and commercialization of CAR T therapies, specifically CARVYKTI for multiple myeloma, which are engineered cell therapies. The company's core platform involves proprietary llama-derived single-domain antibody technology and dual-binding CAR design to modify cells for oncology treatment.
TARS
Tarsus Pharmaceuticals
$3.93Bn
90.78
+9.10%
+58.07%
Tarsus Pharmaceuticals develops and markets branded prescription drugs, specifically XDEMVY lotilaner ophthalmic solution for the treatment of Demodex blepharitis. The company generates the majority of its revenue from the sales of this branded pharmaceutical product to eye care professionals and patients.
ADPT
Adaptive Biotechnologies
$3.86Bn
24.28
-1.18%
+88.95%
The company generates significant revenue through clinical diagnostic testing, specifically its FDA-authorized clonoSEQ assay used by clinicians, hospitals, and cancer centers for minimal residual disease detection in lymphoid malignancies.
CPRX
Catalyst Pharmaceuticals
$3.85Bn
31.49
+0.00%
+49.88%
Catalyst Pharmaceuticals is a commercial-stage company that markets branded prescription drugs for rare diseases, specifically FIRDAPSE, AGAMREE, and FYCOMPA. Its revenue is primarily derived from the sale of these branded pharmaceutical products to patients and physicians.
IDYA
IDEAYA Biosciences
$3.84Bn
39.86
-0.28%
+54.74%
IDEAYA Biosciences is a precision medicine oncology company that researches and develops therapies derived from biological science, including antibody-drug conjugates (ADCs) like IDE849 and IDE034. Its revenue model consists of upfront payments, milestone payments, and royalties from collaborations with partners such as Servier and Novartis, which is characteristic of biotechnology developers.
AMLX
Amylyx Pharmaceuticals
$3.80Bn
34.10
+0.41%
+246.54%
Amylyx is a clinical-stage company developing therapies derived from biological science, specifically antisense oligonucleotides like AMX0114 and GLP-1 receptor antagonists like avexitide. Its revenue model currently relies on collaborations and grants to fund the development of these biologic-based drug candidates.
TNGX
Tango Therapeutics
$3.79Bn
22.52
-1.05%
+236.12%
Tango Therapeutics is a biotechnology company that researches and develops therapies derived from biological science, specifically using synthetic lethality to target cancer cells. Its revenue is currently derived from collaboration and licensing agreements with pharmaceutical firms, which is a characteristic revenue model for clinical-stage biotech developers.
PLSE
Pulse Biosciences
$3.77Bn
53.24
-2.69%
+255.17%
Pulse Biosciences designs and manufactures therapeutic medical devices, specifically the nPulse System and the Vybrance Percutaneous Electrode System, used for nonthermally ablating targeted cells in cardiology and soft tissue. These are surgical and treatment devices sold to hospitals and surgical centers.
RCUS
Arcus Biosciences
$3.77Bn
29.65
-1.59%
+156.49%
Arcus Biosciences is a biopharmaceutical company developing therapies derived from biological science, specifically antibody therapies like domvanalimab and zimberelimab. Its revenue model currently relies on collaboration and licensing agreements, milestone payments, and royalties, which is characteristic of biotechnology developers.
OPCH
Option Care Health
$3.63Bn
24.21
-1.02%
-15.88%
Option Care Health is the largest independent provider of home and alternate site infusion services, delivering clinical management and nursing support where the patient lives. Its revenue is derived from Medicare, Medicaid, and managed care reimbursements for home-based infusion therapy and nursing services.
OGN
Organon
$3.62Bn
13.78
+0.00%
+40.18%
Organon's primary revenue comes from the sale of branded prescription pharmaceuticals, specifically its Women's Health segment featuring products like Nexplanon and NuvaRing. The company markets these branded medicines across therapeutic areas including contraception, fertility, and cardiovascular health.
GRAL
Grail
$3.59Bn
80.34
-0.35%
+147.81%
GRAIL provides clinical diagnostic testing services through its Galleri blood-based test, which is sold to employers, health systems, and payors. The company operates a high-capacity laboratory capable of processing up to one million tests per year to provide these diagnostic results.
DNLI
Denali Therapeutics
$3.56Bn
22.28
-2.28%
+45.53%
Denali Therapeutics is a biotechnology company developing therapies derived from biological science, specifically using its TransportVehicle platform to deliver antibodies, enzymes, and oligonucleotides. Its current revenue is derived from collaboration and milestone payments from partners like Biogen, Takeda, and Sanofi.
ABCL
AbCellera Biologics
$3.50Bn
11.43
-1.21%
+174.76%
AbCellera is a clinical-stage biotechnology company that researches and develops antibody medicines, including multispecific formats and antibody-drug conjugates. Its revenue model is based on biologic-focused partnership payments, milestones, and royalties from collaborators like Eli Lilly and Regeneron.
CRVL
Corvel
$3.47Bn
68.23
-0.66%
-20.64%
CorVel provides managed care and cost containment services, including pharmacy services and preferred provider network access, to insurance companies and self-insured employers. Its revenue is derived from managing medical costs for workers compensation and group health, which aligns with the pharmacy-benefit management and managed-care fee structures described in H-18.
NHC
National Healthcare
$3.42Bn
218.63
-1.42%
+94.77%
The company's primary revenue (96.8%) comes from healthcare services, specifically operating skilled nursing facilities, assisted living, independent living, and homecare and hospice agencies. These activities match the H-15 description of delivering care in residential settings and the home.
VCYT
Veracyte
$3.42Bn
42.53
-4.79%
+38.90%
Veracyte operates CLIA certified laboratories in South San Francisco, San Diego, and Austin to perform laboratory developed tests such as Afirma and Decipher Prostate. The majority of its revenue is generated from these diagnostic-testing service fees paid by Medicare and private commercial payers.
SXI
2nd
Standex International
$3.32Bn
275.64
-0.28%
+38.17%
The Scientific segment manufactures medical-grade and laboratory temperature-controlled equipment, including ultra-low temperature freezers, blood bank refrigerators, and environmental stability chambers sold to healthcare facilities and laboratories.
IPGP
2nd
Ipg Photonics
$3.32Bn
78.00
+2.01%
-3.85%
The company sells laser solutions specifically for medical procedures and to medical device companies, representing a material portion of its non-industrial revenue.
OSIS
2nd
Osi Systems
$3.25Bn
204.15
-1.20%
-12.34%
The Healthcare segment provides diagnostic imaging systems, ultrasound systems, and fetal Doppler devices to hospitals and clinics, which are clinical diagnostic equipment and tests.
TMDX
TransMedics
$3.12Bn
89.98
+3.45%
-13.52%
TransMedics designs and manufactures the Organ Care System (OCS), a portable warm perfusion platform used for heart, lung, and liver transplantation. This is a therapeutic medical device sold to transplant centers and hospitals.
CLDX
Celldex Therapeutics
$3.11Bn
39.68
+0.79%
+68.06%
Celldex Therapeutics is a biopharmaceutical company focused on developing therapies derived from biological science, specifically monoclonal and bispecific antibodies like barzolvolimab and CDX-622. Its revenue model currently consists of partnership agreements, licensing arrangements, and milestone payments from collaborators, which is characteristic of clinical-stage biotechnology developers.
QURE
uniQure
$3.09Bn
44.50
-0.80%
+156.04%
uniQure is a clinical-stage gene therapy company that uses a proprietary adeno-associated virus (AAV) vector platform to develop treatments for genetic diseases. Its pipeline includes gene-based therapies such as AMT-130 for Huntington's disease and AMT-191 for Fabry disease, and it earns revenue from royalties on the gene therapy HEMGENIX.
BEAM
Beam Therapeutics
$3.06Bn
29.66
+0.68%
+58.10%
Beam Therapeutics focuses on precision genetic medicines using a proprietary base editing technology to modify DNA. The company develops therapies for genetic disorders such as sickle cell disease and alpha 1 antitrypsin deficiency, which fits the core platform of genetic modification described in H-03.
IRON
Disc Medicine
$3.04Bn
79.23
-0.18%
+31.63%
Disc Medicine is a clinical-stage biopharmaceutical company developing therapies derived from biological science to treat hematologic diseases. Its revenue model currently relies on licensing agreements and milestone payments for candidates like bitopertin, DISC 0974, and DISC 0998.
IMNM
Immunome
$3.03Bn
26.76
-1.47%
+173.06%
Immunome is a clinical-stage biotechnology company developing therapies derived from biological science, specifically antibody-drug conjugates (ADCs) like IM-1021 and radioligand therapies like IM-3050. Its revenue model is based on strategic partnerships, licensing agreements, and milestone payments typical of biotech developers.
WRBY
2nd
Warby Parker
$3.00Bn
24.35
+4.51%
-3.60%
The company provides professional eye exams and vision tests conducted by clinicians within its physical retail locations.
ARQT
Arcutis Biotherapeutics
$3.00Bn
23.90
+1.01%
+47.44%
Arcutis is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically targeting immune-mediated dermatological conditions. Its revenue is generated from the sales of ZORYVE products and collaboration/milestone payments from partners like Huadong and Sato.
NAMS
NewAmsterdam Pharma
$2.99Bn
25.40
-1.74%
+2.09%
NewAmsterdam Pharma is developing obicetrapib, a branded prescription drug for cardiometabolic diseases and Alzheimer's. The company plans to commercialize this small-molecule CETP inhibitor independently in the US and via licensing in Europe, generating revenue from direct sales, milestone payments, and royalties.
AVAH
Aveanna Healthcare Holdings
$2.96Bn
13.58
-0.44%
+62.83%
Aveanna provides home-based clinical care including private duty nursing for medically complex children and adults, as well as home health and hospice services for elderly populations. These services are delivered in the patient's home and reimbursed by Medicaid, Medicare, and commercial insurers.
MBX
MBX Biosciences
$2.96Bn
61.72
+0.49%
+328.61%
MBX Biosciences is a clinical-stage biopharmaceutical company developing peptide therapies, such as the GLP 1/GIP co agonist MBX 4291 and the parathyroid hormone prodrug canvuparatide. These are biological science-derived therapies (peptides) developed using its proprietary PEP platform.
ZLAB
Zai Lab
$2.94Bn
26.23
-2.85%
-12.57%
Zai Lab is a biopharmaceutical company that commercializes therapies derived from biological science, including antibody-drug conjugates like Zoci (ZL-1310) and biologics such as VYVGART and VYVGART Hytrulo. Its revenue is derived from the sales of these innovative biologic products and its pipeline focuses on biology-based drug discovery.
CHRN
ChronoScale Holdings
$2.94Bn
20.26
+0.90%
+378.96%
The company designs and manufactures wearable robotic exoskeletons for clinical and personal use, such as the EksoNR and Ekso Indego Therapy units. These are therapeutic and surgical medical devices used for physical rehabilitation and mobility for individuals with physical disabilities.
BKD
Brookdale Senior Living
$2.81Bn
11.77
-1.42%
+54.26%
Brookdale operates senior living communities providing independent living, assisted living, and memory care, which are residential settings where patients live. Revenue is generated from resident fees paid by private individuals and government reimbursement programs like Medicare and Medicaid.
ALHC
Alignment Healthcare
$2.81Bn
13.54
-0.07%
-16.93%
Alignment Healthcare operates as a Medicare Advantage plan provider, contracting directly with CMS to manage healthcare for seniors. Its revenue model is based on capitated, fixed monthly payments per enrolled member (PMPM), which is the hallmark of health insurance and managed-care plans.
SLS
SELLAS Life Sciences
$2.80Bn
13.86
+1.17%
+678.65%
SELLAS is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically galinpepimut S, a peptide immunotherapy. Its revenue is currently generated through milestone and royalty payments from collaboration agreements, such as the one with 3D Medicines.
ATAI
AtaiBeckley
$2.73Bn
7.39
+0.68%
+62.06%
Atai is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically psychedelic-based therapies and novel compounds like dimethyltryptamine and psilocin. Its revenue model is based on the typical biotechnology pattern of collaboration, milestone payments, and future royalties/sales of biologic-based drug candidates.
ATAI
AtaiBeckley
$2.73Bn
7.39
+0.68%
+62.06%
AtaiBeckley is a clinical-stage biotechnology company developing therapies derived from biological science, specifically psychedelic-based neuroplastogens. Its pipeline includes biological-based candidates like BPL 003 (mebufotenin benzoate) and VLS 01 (dimethyltryptamine) for treatment-resistant depression.
NRIX
Nurix Therapeutics
$2.71Bn
26.14
+3.24%
+186.62%
Nurix Therapeutics is a clinical-stage biopharmaceutical company that develops therapies derived from biological science, specifically targeted protein degradation medicines. Its revenue is derived from collaboration and milestone payments from partners like Gilead, Sanofi, and Pfizer, and it focuses on biology-based drug discovery using its DEL-AI platform.
TAK
Takeda Pharmaceutical
$2.67Bn
18.47
-1.23%
+21.91%
Takeda is a global pharmaceutical company that develops and markets branded prescription drugs across multiple therapeutic areas. Its revenue is driven by branded products such as ENTYVIO for inflammatory bowel disease and VYVANSE for ADHD.
ATRC
AtriCure
$2.62Bn
51.52
-1.79%
+44.48%
AtriCure designs and manufactures therapeutic and surgical medical devices, specifically ablation platforms like the Isolator Synergy and left atrial appendage exclusion systems like AtriClip. These products are sold to hospitals and surgical centers for use in open heart and minimally invasive cardiac procedures.
CDNA
CareDx
$2.62Bn
50.88
+2.05%
+299.69%
CareDx generates significant revenue from providing clinical diagnostic testing services, such as AlloSure Kidney and AlloMap Heart, which are performed in its Brisbane, California laboratory and reimbursed by Medicare and private payers.
CURLF
2nd
Curaleaf Holdings
$2.61Bn
9.86
+3.46%
+19.95%
The company operates a medical cannabis clinic in the United Kingdom, providing direct medical services and care to patients in a clinic setting.
PRVA
Privia Health
$2.61Bn
20.66
-0.05%
-10.64%
Privia Health operates as a physician enablement company that organizes providers into Medical Groups and manages care delivery across more than 1,300 practice locations. It generates significant revenue from fee-for-service patient care, capitated payments, and management fees for providing practice support and revenue cycle management to physician groups.
VRDN
Viridian Therapeutics, Inc.\DE
$2.60Bn
22.92
-0.17%
+17.72%
Viridian Therapeutics is a biopharmaceutical company developing therapies derived from biological science, specifically monoclonal antibodies like veligrotug and elegrobart. Its product pipeline focuses on biology-based drug discovery for thyroid eye disease and autoimmune disorders.
AXGN
Axogen
$2.59Bn
48.28
+2.51%
+213.51%
Axogen designs and manufactures therapeutic medical devices for nerve repair, specifically the Axoguard product line (Nerve Connector, Nerve Protector, and Nerve Cap) which are cleared via the FDA 510(k) pathway. These products are sold to hospitals and surgery centers for use in surgical procedures to support nerve coaptation and neuroma prevention.
VERA
Vera Therapeutics
$2.59Bn
35.89
+2.57%
+56.32%
Vera Therapeutics is a biotechnology company developing therapies derived from biological science, specifically atacicept, which is a human TACI Fc fusion protein. The company also develops MAU868, a monoclonal antibody, both of which are biologic-based drug candidates.
NEOG
Neogen
$2.58Bn
11.83
+1.63%
+106.82%
Neogen's primary revenue driver is its Food Safety segment (71.3% of sales), which develops and markets diagnostic test kits for pathogen, toxin, and allergen detection, as well as culture media. These products are sold to food producers, processors, and regulatory agencies like the USDA and FDA for clinical and safety diagnostics.
WGS
GeneDx Holdings
$2.56Bn
85.99
-1.60%
-32.41%
GeneDx generates its primary revenue from the sale of diagnostic test reports for exome and genome sequencing, such as ExomeDx and GenomeDx. The company operates CLIA-certified high-complexity laboratories to provide these clinical laboratory and genetic testing services to hospitals, clinics, and clinicians.
ACHC
Acadia Healthcare Company
$2.56Bn
28.13
-0.88%
+18.94%
Acadia operates acute inpatient psychiatric facilities that provide 24-hour observation and crisis stabilization for severe psychiatric diagnoses. These are licensed inpatient facilities where revenue is derived from facility-based care reimbursed by Medicaid, Medicare, and commercial insurers.
BCRX
Biocryst Pharmaceuticals
$2.54Bn
9.96
-1.29%
+20.14%
BioCryst is a biotechnology company that develops and commercializes therapies derived from biological science, specifically monoclonal antibodies like Navenibart and STAR-0310, and protein therapeutics like BCX17725. Its revenue model includes biologic product sales, licensing agreements, and milestone payments from collaborators such as Torii Pharmaceutical and Shionogi.
PGEN
Precigen
$2.54Bn
7.10
-0.56%
+49.47%
Precigen's core business is the development and commercialization of gene and cell therapies, utilizing its proprietary AdenoVerse and Ultra CAR T platforms. Its lead approved product, Papzimeos, and its pipeline targeting cancers (PRGN 2009, 3005, 3006, 3007) are based on genetic and cellular modification.
LIFE
Ethos Technologies
$2.54Bn
39.85
+5.67%
—
Ethos Technologies delivers clinical care and remote patient monitoring services for chronic conditions like heart failure and diabetes. It employs a team of registered nurses and care managers to monitor patient data and initiate outreach, which aligns with the delivery of remote clinical care.
SUPN
Supernus Pharmaceuticals
$2.53Bn
43.53
-1.00%
-3.12%
Supernus Pharmaceuticals develops and markets branded prescription drugs for CNS diseases, such as Qelbree for ADHD and ZURZUVAE for postpartum depression. Its revenue is primarily generated from the sale of these proprietary branded pharmaceuticals to wholesalers and specialty pharmacies.
MLYS
Mineralys Therapeutics
$2.49Bn
28.21
-0.21%
-14.82%
Mineralys Therapeutics is developing lorundrostat, an oral aldosterone synthase inhibitor, which is a branded prescription drug candidate for hypertension and cardiorenal conditions. The company's core business is the discovery and development of this small-molecule pharmaceutical to treat diseases driven by dysregulated aldosterone.
HCM
HUTCHMED (China)
$2.46Bn
14.09
-0.14%
-7.73%
HUTCHMED is a biopharmaceutical company focused on the discovery and development of targeted therapies and immunotherapies, such as savolitinib and fruquintinib. Its revenue is derived from the sale of these biologic-focused oncology drugs and milestone payments from partners like AstraZeneca and Eli Lilly.
TRVI
Trevi Therapeutics
$2.46Bn
17.26
+1.17%
+141.40%
Trevi Therapeutics is a clinical-stage company developing Haduvio (oral nalbuphine ER), which is a small-molecule branded prescription drug candidate for chronic cough. The company's focus is on the discovery and development of this branded pharmaceutical therapy for patients with idiopathic pulmonary fibrosis and refractory cough.
HRMY
Harmony Biosciences Holdings
$2.46Bn
42.25
+0.93%
+12.58%
Harmony Biosciences discovers, develops, and markets branded prescription drugs for rare neurological diseases, with the vast majority of its revenue coming from the sale of its branded product WAKIX (pitolisant). The company's business model is centered on branded pharmaceutical sales to specialty pharmacies and distributors.
BHC
Bausch Health Companies
$2.45Bn
6.56
-2.96%
-10.75%
The company describes itself as a diversified specialty pharmaceutical company with significant revenue from generic and branded generic pharmaceuticals, as well as niche specialty products in gastroenterology and neuroscience.
NKTR
Nektar Therapeutics
$2.45Bn
74.19
-2.85%
+106.20%
Nektar Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically immunomodulatory agents and biologics like NKTR-255 targeting the IL-15 pathway. Its revenue model is based on collaboration agreements, royalties, and milestone payments from partnered drug programs.
XTLB
Xtl Biopharmaceuticals
$2.38Bn
2.52
-1.18%
-46.61%
The company develops and commercializes biopharmaceutical intellectual property, specifically the hCDR1 synthetic peptide for treating systemic lupus erythematosus and Sjogren’s syndrome. It generates revenue through a sublicense agreement with Biossil Inc., including potential milestone payments.
SRPT
Sarepta Therapeutics
$2.38Bn
22.50
-2.13%
+18.73%
Sarepta's core business is the development and commercialization of genetic modalities, specifically gene therapy as evidenced by its product ELEVIDYS and its use of the AAVrh.74 vector. The company focuses on modifying or replacing genes to treat rare diseases like Duchenne muscular dystrophy.
BHVN
Biohaven
$2.37Bn
15.69
-1.07%
-2.36%
Biohaven is a clinical-stage biopharmaceutical company developing therapies derived from biological science, including antibody-drug conjugates (ADCs) like BHV-1510 and BHV-1530 in its oncology segment. Its business model focuses on biology-based drug discovery and development across immunology, neuroscience, and oncology.
NUVB
Nuvation Bio
$2.36Bn
6.81
+0.59%
+99.12%
Nuvation Bio develops and markets branded prescription oncology drugs, specifically the FDA-approved IBTROZI for ROS1 positive non small cell lung cancer. Its revenue is generated through direct product sales in the US and licensing/royalties from partners like Eisai and Nippon Kayaku.
OCUL
Ocular Therapeutix
$2.34Bn
10.64
+0.00%
-17.77%
Ocular Therapeutix is a biopharmaceutical company utilizing its proprietary ELUTYX hydrogel technology platform to develop therapies. Its revenue is derived from the sale of DEXTENZA, a corticosteroid insert, and milestone payments from collaborations for biologic-based delivery systems.
PHVS
Pharvaris
$2.30Bn
35.25
-1.15%
+60.37%
Pharvaris is a biopharmaceutical company developing deucrictibant, a novel oral therapy targeting the bradykinin B2 receptor for rare diseases. Its business model is centered on the research, development, and planned commercialization of these biological-science-based therapies.
XRAY
Dentsply Sirona
$2.27Bn
11.38
-0.44%
-18.19%
The company is the world's largest manufacturer of professional dental products, selling clear aligners (SureSmile), dental implants, and CAD/CAM systems (CEREC) to dental professionals and laboratories.
PVLA
Palvella Therapeutics
$2.26Bn
157.24
+1.14%
+193.85%
Palvella Therapeutics is a biopharmaceutical company developing branded prescription topical therapies, such as QTORIN rapamycin and QTORIN pitavastatin, for rare skin diseases. These are small-molecule active ingredients (rapamycin and pitavastatin) formulated into gels, fitting the profile of branded pharmaceutical development.
CLOV
Clover Health Investments
$2.25Bn
4.26
+0.00%
+58.36%
Clover Health generates its primary revenue from insurance premiums earned on its Medicare Advantage PPO and HMO plans for seniors. It operates as a managed care organization competing with national insurers like United Health Group and Humana.
MESO
Mesoblast
$2.24Bn
17.32
+1.05%
+34.47%
Mesoblast develops allogeneic cellular medicines using a proprietary mesenchymal lineage cell therapy platform to create off-the-shelf therapies. Its lead product, Ryoncil, is a mesenchymal stromal cell therapy approved for pediatric graft versus host disease.
UFPT
Ufp Technologies
$2.24Bn
288.79
+0.79%
+38.28%
UFP Technologies designs and manufactures medical devices and components used in minimally invasive surgery, orthopedic implants, and wearables for customers like Intuitive Surgical and Stryker. While it operates as a contract partner, its primary output consists of therapeutic and surgical medical devices.
NEO
Neogenomics
$2.22Bn
17.38
-0.46%
+112.21%
NeoGenomics operates a network of cancer-focused testing laboratories providing clinical oncology diagnostic testing, including molecular and NGS testing. Its revenue is generated through diagnostic-testing service fees for services like cytogenetics, FISH, and flow cytometry sold to healthcare providers and hospitals.
KOD
Kodiak Sciences
$2.22Bn
35.36
-2.75%
+312.60%
Kodiak Sciences develops therapies derived from biological science, specifically using an Antibody Biopolymer Conjugate (ABC) platform to create monoclonal antibodies and bispecific proteins like tarcocimab tedromer (Zenkuda) and KSI-501. The company is a clinical-stage developer focusing on biology-based drug discovery for retinal diseases.
ADUS
Addus HomeCare
$2.22Bn
118.76
+0.06%
+5.00%
Addus HomeCare provides in-home care services including personal care, hospice, and home health to elderly and disabled individuals. Its revenue is derived from Medicare, Medicaid, and private pay for services delivered where the patient lives, such as non-medical assistance with daily living and palliative care.
ESTA
Establishment Labs Holdings
$2.21Bn
74.29
+2.75%
+93.61%
Establishment Labs designs and manufactures therapeutic and surgical medical devices, specifically the Motiva Implants silicone gel filled breast implants and the Motiva Flora tissue expander. These products are sold to hospitals, outpatient surgery centers, and plastic surgeons for use in breast aesthetics and reconstruction.
MD
Pediatrix Medical
$2.20Bn
27.04
+0.60%
+58.97%
Pediatrix provides physician services specializing in newborn, maternal-fetal, and pediatric subspecialty care delivered in clinical and hospital-based settings. Its revenue is generated through patient service fees for these outpatient and specialty physician services rendered to expectant mothers and infants.
RAPP
Rapport Therapeutics
$2.19Bn
45.77
-3.95%
+204.32%
Rapport Therapeutics is a clinical-stage biotechnology company developing small molecule precision medicines, such as its lead candidate RAP 219, for neurological and psychiatric disorders. Its business model relies on its RAP technology platform for biology-based drug discovery and development.
ADMA
Adma Biologics
$2.17Bn
9.62
+0.42%
-43.08%
Adma Biologics is a biopharmaceutical company that develops and manufactures biologics derived from human plasma, specifically immune globulin products like ASCENIV, BIVIGAM, and Nabi HB. Its core revenue is derived from the sale of these biologic therapies used to treat immunodeficient patients.
ASST
2nd
Strive
$2.16Bn
27.14
+1.19%
—
Through its subsidiary Semler Scientific, the company markets the QuantaFlo FDA cleared vascular testing device, which is a sensor-based product used for in-office blood flow tests. Revenue is derived from licensing fees and service agreements tied to the volume of tests performed using this diagnostic equipment.
GMAB
Genmab A
$2.16Bn
33.60
-2.35%
+22.72%
Genmab is a biotechnology company that develops and commercializes antibody-based therapies, such as epcotamab and tisotumab vedotin. Its revenue is derived from biologic product sales, royalties from partnered biologics like daratumumab and rybrevant, and milestone payments from collaborations with partners like AbbVie and BioNTech.
URGN
UroGen Pharma
$2.16Bn
44.09
-1.76%
+127.62%
UroGen Pharma is described as a biotechnology company that develops therapies derived from biological science, specifically utilizing its proprietary RTGel reverse thermal hydrogel platform. Its revenue is generated from the sale of biologic-based products like Jelmyto and Zusduri, as well as potential milestone payments and royalties from licensing agreements.
AUPH
Aurinia Pharmaceuticals
$2.14Bn
16.08
-0.25%
+34.00%
Aurinia Pharmaceuticals develops and markets branded prescription drugs, specifically its flagship oral therapy LUPKYNIS for lupus nephritis. The company generates the majority of its revenue from the direct sale of this branded pharmaceutical product in the U.S. and through royalties and supply agreements internationally.
FMS
Fresenius Medical Care AG
$2.11Bn
22.66
+0.89%
-6.98%
The company operates the world's largest network of 3,601 dialysis centers, providing in-center kidney replacement therapies and outpatient vascular care. This segment, Care Delivery, serves nearly 300,000 patients through a global network of clinics and physician partnerships.
NVCR
NovoCure
$2.09Bn
17.94
+1.70%
+48.51%
NovoCure designs and manufactures therapeutic medical devices, specifically the Optune and Optune Lua systems, which deliver tumor treating fields therapy to patients with solid tumor cancers. Its revenue is generated primarily through the sale of these devices and associated accessory systems.
ZYME
Zymeworks
$2.08Bn
29.19
-2.37%
+106.44%
Zymeworks is a biotechnology company that develops therapies derived from biological science, specifically multispecific antibodies and antibody-drug conjugates like ZW191 and ZW220. Its revenue is derived from biologic product collaborations, milestone payments, and royalties from partners such as Jazz Pharmaceuticals and BeOne.
ZBIO
Zenas BioPharma
$2.08Bn
32.88
-0.12%
+91.83%
Zenas BioPharma is a clinical-stage biopharmaceutical company focusing on therapies derived from biological science, specifically monoclonal antibodies like obexelimab. Its revenue model currently consists of upfront licensing payments, milestone payments, and royalties from partners such as Bristol Myers Squibb and InnoCare.
VCEL
Vericel
$2.06Bn
40.19
-0.69%
+19.79%
Vericel's core business is the development and commercialization of autologous cell therapies, specifically MACI for cartilage repair and Epicel for severe burns. These products involve the modification and application of a patient's own cells, which aligns directly with the Gene and Cell Therapy classification.
PGNY
Progyny
$2.01Bn
25.94
-2.52%
+10.20%
Progyny delivers healthcare services by managing a selective network of healthcare providers for fertility, pregnancy, and postpartum care. It earns revenue through per-member-per-month charges for care management services and clinical support delivered to members of its employer-sponsored programs.
XNCR
Xencor
$1.98Bn
26.61
-0.04%
+219.45%
Xencor is a clinical-stage biopharmaceutical company that develops engineered antibody therapeutics, specifically using its XmAb platform to create bispecific antibodies and recombinant proteins. Its revenue is derived from biologic product collaborations, milestone payments, and royalties from marketed medicines like Monjuvi and Ultomiris.
AGIO
Agios Pharmaceuticals
$1.97Bn
33.10
-0.09%
-18.49%
Agios is a biopharmaceutical company that leverages expertise in cellular metabolism to develop therapies for rare diseases, such as PYRUKYND® and AQVESME™. Its revenue is derived from the sale of these biologic-focused medicines, as well as milestone payments and royalties from licensing arrangements like the AG 236 siRNA program.
RXRX
Recursion Pharmaceuticals
$1.94Bn
3.63
+5.52%
-19.69%
Recursion is a clinical-stage biotechnology company that researches and develops therapies using a proprietary drug discovery platform. Its revenue is derived from collaboration and milestone payments from pharmaceutical partners like Roche, Genentech, and Sanofi.
VIR
Vir Biotechnology
$1.93Bn
11.39
-0.52%
+121.60%
Vir Biotechnology is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically antibody combinations and T cell engagers. Its revenue is currently generated through collaboration and licensing agreements, milestone payments, and royalties, which is characteristic of the Biotechnology industry.
EPAC
2nd
Enerpac Tool
$1.91Bn
37.36
+1.11%
-11.82%
Through its Cortland Biomedical business, the company operates as a biomedical textile product development company, which falls under the manufacture of medical supplies and consumables.
MRVI
Maravai Lifesciences Holdings
$1.90Bn
7.32
-0.68%
+210.17%
Maravai sells complex nucleic acids, custom enzymes, and antibody-based solutions used for research and biopharmaceutical production. These products, including mRNA oligonucleotides and nucleoside triphosphates, are sold to biopharmaceutical companies, biotech firms, and academic research institutions as life-sciences research tools and bioprocessing supplies.
ASTH
Astrana Health
$1.89Bn
38.47
+1.69%
+25.31%
Astrana Health is a risk-bearing healthcare company that generates significant revenue from capitation payments and risk pool settlements, assuming financial responsibility for patient care. It organizes risk-bearing entities such as state-licensed health plans and acts as a single payer for its network, which aligns with the managed care and insurance risk-bearing model.
NBTX
Nanobiotix
$1.88Bn
38.80
-3.00%
+348.04%
Nanobiotix is a clinical-stage biotechnology company developing nanotherapeutics, such as the hafnium oxide-based nanoparticle JNJ-1900 (NBTXR3). Its revenue model is based on biotechnology-typical sources, including strategic collaborations, licensing agreements, and milestone payments from partners like Janssen Pharmaceutica NV.
LKFT
Lakefront Biotherapeutics
$1.88Bn
28.49
-1.83%
-10.72%
Galapagos NV is a biotechnology company that researches and develops therapies for immunology and oncology, generating revenue from collaboration payments and royalties. Its business model focuses on biology-based drug discovery and development, as evidenced by its pipeline of therapeutic programs.
SGRY
Surgery Partners
$1.87Bn
14.26
+0.64%
-36.65%
Surgery Partners operates a national network of ambulatory surgery centers, urgent care facilities, and multi-specialty physician practices. Its revenue is primarily derived from facility fees for outpatient surgical procedures and related ancillary care provided in these clinic settings.
STOK
Stoke Therapeutics
$1.86Bn
29.81
-0.60%
+50.78%
Stoke Therapeutics develops RNA-based medicines, specifically antisense oligonucleotides (ASOs), which are categorized as oligonucleotide medicines under Biotechnology. The company's revenue is derived from collaboration and milestone payments from partners like Acadia Pharmaceuticals and Biogen, typical for clinical-stage biotech developers.
IMCR
Immunocore Holdings
$1.86Bn
36.13
-3.83%
+2.44%
Immunocore is a biotechnology company that develops therapies derived from biological science, specifically using its ImmTAX platform to engineer T-cell receptors. It generates revenue from the sale of KIMMTRAK (tebentafusp), a biologic product used to treat uveal melanoma.
DMRA
Damora Therapeutics
$1.86Bn
30.06
+7.36%
+912.12%
Damora Therapeutics is a biopharmaceutical company developing monoclonal antibodies, specifically DMR-001, DMR-002, and DMR-003, to treat hematologic disorders. These are therapies derived from biological science targeting the mutant calreticulin protein (mutCALR), which fits the definition of biotechnology.
LMAT
Lemaitre Vascular
$1.84Bn
80.67
+0.22%
-16.90%
Lemaitre Vascular designs and manufactures therapeutic and surgical medical devices, including anastomotic clips, carotid shunts, embolectomy catheters, and valvulotomes. These products are sold primarily to hospitals and clinics for use by vascular and cardiac surgeons in open and minimally invasive procedures.
SNDX
Syndax Pharmaceuticals
$1.83Bn
20.56
-0.58%
+27.46%
Syndax is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically monoclonal antibodies like Niktimvo (axatilimab). Its revenue is generated from the sales of these biologic products, as well as collaboration milestones and royalties.
PSNL
Personalis
$1.83Bn
17.20
+2.20%
+237.92%
Personalis provides clinical laboratory and diagnostic testing services, specifically cancer genomic testing, through its CLIA-certified and CAP-accredited high-complexity laboratory. Its revenue is generated from performing tests such as NeXT Personal Dx and NeXT Dx for pharmaceutical companies, diagnostic partners, and cancer patients.
INSP
Inspire Medical Systems
$1.82Bn
63.06
+1.61%
-26.33%
Inspire Medical Systems designs and manufactures the Inspire system, a neurostimulation medical device used to treat obstructive sleep apnea. The company generates its primary revenue from selling this therapeutic implant to hospitals and ambulatory surgery centers.
TSHA
Taysha Gene Therapies
$1.82Bn
5.60
+0.54%
+93.10%
Taysha Gene Therapies is a clinical-stage company developing adeno-associated virus (AAV)-based gene therapies, specifically TSHA-102 for Rett syndrome. Its core platform involves modifying genes to treat monogenic diseases of the central nervous system, which aligns directly with the Gene and Cell Therapy classification.
CMPS
COMPASS Pathways
$1.80Bn
13.27
-0.15%
+160.20%
Compass Pathways is a clinical-stage biotechnology company developing COMP360, a proprietary formulation of psilocybin for treatment-resistant depression and PTSD. Its business model focuses on biology-based drug discovery and development, currently financing operations through equity and collaboration agreements while conducting Phase 2b and Phase 3 clinical trials.
SNDA
Sonida Senior Living
$1.79Bn
37.72
-0.32%
+48.97%
Sonida Senior Living operates senior housing communities providing independent living, assisted living, and memory care services. It generates revenue through residential fees for housing and care services provided to residents aged 75 and older.
NTLA
Intellia Therapeutics
$1.78Bn
12.74
+0.47%
+8.80%
Intellia Therapeutics is a clinical-stage company focused on developing CRISPR-based therapies, specifically utilizing a proprietary CRISPR/Cas9 platform for in vivo and ex vivo gene editing. Its lead programs, lonvo-z and nex-z, are designed to modify genes to treat hereditary angioedema and transthyretin amyloidosis.
INBX
Inhibrx Biosciences
$1.78Bn
121.17
-0.89%
+335.86%
Inhibrx is a clinical-stage biopharmaceutical company developing biologic therapeutics, specifically multi-specific biologics and agonists like ozekibart and INBRX 106. Its revenue model is based on potential milestone and royalty payments from collaborations, which is characteristic of biotechnology developers.
BFLY
Butterfly Network
$1.75Bn
7.36
+0.96%
+390.67%
Butterfly Network manufactures and sells clinical diagnostic equipment, specifically handheld ultrasound devices like the Butterfly iQ3 and Butterfly iQ+, which are used for point-of-care imaging. Its revenue is driven by the sale of these diagnostic instruments and the associated AI-driven software and consumables.
GHRS
GH Research
$1.75Bn
28.23
+1.11%
+100.93%
GH Research is a clinical-stage biopharmaceutical company developing mebufotenin-based therapies, such as GH001 and GH002, for psychiatric and neurological disorders. Its business model focuses on biology-based drug discovery and development for treatment-resistant depression.
SCNI
Scinai Immunotherapeutics
$1.74Bn
1.86
-4.62%
+15.53%
Scinai Immunotherapeutics is a biopharmaceutical company developing therapies derived from biological science, specifically monoclonal antibodies and NanoAbs for inflammatory diseases like psoriasis and pemphigus. Its R&D segment focuses on the discovery and development of these biologic-based drug candidates.
BLFS
Biolife Solutions
$1.72Bn
35.25
-0.79%
+36.26%
Biolife Solutions provides tools, reagents, and consumables for bioproduction and life-sciences research, specifically biopreservation media like HypoThermosol® FRS and CryoStor® Freeze Media. Its customers include academic research institutions and biopharma manufacturers using these tools for basic and applied research.
TYRA
Tyra Biosciences
$1.71Bn
28.65
+15.25%
+132.55%
Tyra Biosciences is a clinical-stage biotechnology company that uses its proprietary SNÅP platform to research and develop therapies derived from biological science, specifically small molecule inhibitors targeting FGFR signaling. Its pipeline includes candidates like dabogratinib for urothelial carcinoma and achondroplasia, and TYRA-430 for hepatocellular carcinoma.
ANIP
Ani Pharmaceuticals
$1.70Bn
71.23
-1.06%
-25.80%
ANI Pharmaceuticals focuses on specialty and generic drugs, offering over 120 generic products across various dosage forms. Its 'Generics and Other' segment specifically targets niche opportunities such as paragraph IV filings and competitive generic therapy designations.
NVAX
Novavax
$1.68Bn
10.22
-1.16%
+31.19%
Novavax is a biotechnology company that develops therapies derived from biological science, specifically using a recombinant nanoparticle vaccine technology and a baculovirus insect cell expression system. Its revenue is generated from the sale of its COVID-19 vaccine (Nuvaxovid) and milestone payments from collaborations with partners like Sanofi and Pfizer.
FTRE
Fortrea Holdings
$1.68Bn
17.70
-4.94%
+68.41%
Fortrea is a global contract research organization (CRO) that provides phase I through IV clinical trial management, patient recruitment, and biostatistics for pharmaceutical and medical device sponsors. Its revenue is derived from fee-for-service and full-service outsourcing contracts for clinical research services.
SEPN
Septerna
$1.68Bn
36.75
-0.14%
+161.01%
Septerna is a clinical-stage biotechnology company that uses its proprietary Native Complex Platform to research and develop therapies derived from biological science, specifically targeting G protein coupled receptors. Its revenue is generated through collaboration agreements, upfront payments, and potential milestones with pharmaceutical partners like Novo Nordisk.
ALVO
Alvotech
$1.66Bn
5.32
-1.12%
-33.83%
Alvotech is focused solely on the development and manufacture of biosimilar medicines, which are specifically categorized under H-04. The company's revenue is derived from the sale of these biosimilars and licensing income from partners like Teva and STADA.
AAPG
Ascentage Pharma Group International
$1.66Bn
17.77
+2.36%
-56.98%
Ascentage Pharma is a biopharmaceutical company that researches and commercializes therapies derived from biological science, specifically targeting apoptotic pathways and tyrosine kinase signaling. Its lead assets, Olverembatinib and Lisaftoclax, are developed using a proprietary drug discovery platform focused on biological targets in hematological malignancies.
ETON
Eton Pharmaceuticals
$1.65Bn
58.45
-2.42%
+227.08%
Eton Pharmaceuticals develops and markets branded prescription drugs for rare diseases, such as INCRELEX for insulin-like growth factor 1 deficiency and GALZIN for Wilson disease. Its revenue is derived from the sale of these branded pharmaceutical products to healthcare providers and patients.
ANAB
Anaptysbio
$1.65Bn
56.80
-1.15%
+169.32%
Anaptysbio is a clinical-stage biotechnology company developing antibody-based therapeutics such as rosnilimab, ANB033, and ANB101. Its revenue is derived from biologic-related sources including milestone payments and royalties from collaborations with GSK and Vanda.
FBRX
Forte Biosciences
$1.58Bn
76.99
+0.00%
+589.87%
Forte Biosciences is a clinical-stage biopharmaceutical company developing FB102, which is a monoclonal antibody. Its core business is the research and development of therapies derived from biological science to treat autoimmune diseases.
OMCL
Omnicell
$1.57Bn
34.37
-1.29%
+4.72%
Omnicell designs and manufactures therapeutic and surgical medical devices, specifically automated dispensing cabinets and robotic compounding systems used for medication administration. These hardware products are sold to hospitals, health systems, and pharmacies to improve safety and efficiency in medication management.
PAHC
Phibro Animal Health
$1.55Bn
38.25
-0.86%
+0.16%
The company's primary business is the development, manufacture, and marketing of animal health products, including antibacterials, anticoccidials, vaccines, and vaccine adjuvants for poultry, swine, beef, dairy cattle, and aquaculture.
INVA
Innoviva
$1.55Bn
21.33
-0.09%
+2.06%
Innoviva develops and commercializes a portfolio of branded prescription therapeutics for critical care and infectious diseases, including GIAPREZA, XACDURO, XERAVA, and ZEVTERA. It also earns significant revenue from branded respiratory products developed in collaboration with GSK.
ARDT
Ardent Health
$1.55Bn
10.90
+1.21%
-14.78%
Ardent Health operates a network of 30 acute care hospitals and generates revenue from inpatient acute care reimbursed by Medicare, Medicaid, and commercial health plans.
BCAX
Bicara Therapeutics
$1.53Bn
23.17
-0.73%
+93.08%
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies, specifically ficerafusp alfa, which is a biologic derived from biological science. Its core business is the research and development of these monoclonal antibody-based therapies for solid tumors.
ABSI
Absci
$1.51Bn
8.82
+0.23%
+270.59%
Absci is a clinical-stage biopharmaceutical company that researches and develops antibody-based therapeutics, such as ABS-201, using biological science. Its revenue model includes the development of its own pipeline and receiving milestone payments and royalties from biologic product collaborations.
RARE
Ultragenyx Pharmaceutical
$1.51Bn
15.30
+3.03%
-51.09%
Ultragenyx is a biopharmaceutical company that develops and commercializes therapies derived from biological science, including biologics and enzyme replacement therapies like Mepsevii. Its revenue is generated from the sale of these biologic products and through collaboration agreements and milestone payments with partners such as Kyowa Kirin and Regeneron.
AVBP
ArriVent BioPharma
$1.50Bn
30.95
-0.26%
+58.56%
ArriVent BioPharma is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically antibody-drug conjugates (ADCs) like ARR 217 and ARR 002. Its revenue model currently consists of collaboration and milestone payments, which is characteristic of biotechnology developers.
KMTS
Kestra Medical Technologies
$1.49Bn
25.54
+1.59%
+50.59%
Kestra designs and manufactures the ASSURE WCD, a wearable cardioverter defibrillator used to treat patients at risk of sudden cardiac arrest. This is a therapeutic medical device that monitors heart rhythm and delivers defibrillation shocks.
HCSG
2nd
Healthcare Services
$1.48Bn
21.82
+0.51%
+38.54%
The company provides professional dietitian services and manages dietary departments to meet residents' medical and nutritional needs in outpatient and long-term care settings.
AGL
Agilon Health
$1.48Bn
88.36
+2.20%
+192.10%
Agilon Health forms risk-bearing entities that contract with health plan payors to receive monthly capitated payments for managing the total healthcare needs of Medicare beneficiaries. Its revenue model is based on per-member-per-month fees and the management of insurance risk, which aligns with the Managed Care industry.
XERS
Xeris Biopharma Holdings
$1.48Bn
8.53
-0.70%
+8.80%
Xeris Biopharma develops and markets branded prescription drugs such as Recorlev for Cushing's syndrome, Gvoke for severe hypoglycemia, and Keveyis for Primary Periodic Paralysis. Its revenue is generated through the sale of these branded pharmaceutical products to patients via healthcare provider prescriptions.
CNMD
Conmed
$1.48Bn
49.33
-0.22%
-9.80%
CONMED designs and manufactures therapeutic and surgical medical devices, including powered resection instruments, the Hall surgical brand of battery operated power tools, and electrosurgical generators. These products are sold to hospitals and surgery centers for use in orthopedics, general surgery, and gastroenterology.
SLDB
Solid Biosciences
$1.47Bn
10.25
-1.63%
+78.26%
Solid Biosciences focuses on developing gene therapy candidates using adeno-associated virus (AAV) to deliver functional genes for diseases like Duchenne muscular dystrophy and Friedreich's ataxia. Its core platform is based on genetic modification and proprietary capsid technology for vector delivery.
ATEC
Alphatec Holdings
$1.46Bn
9.45
+1.29%
-40.57%
Alphatec designs and manufactures spinal implants, instruments, and neuromonitoring systems used for the surgical treatment of spine disorders. These products are sold to hospitals and ambulatory surgery centers for use in spinal fusion and decompression procedures.
INNV
InnovAge Holding
$1.46Bn
10.75
-0.19%
+194.52%
InnovAge provides comprehensive in-home care (skilled, unskilled, and personal) and supportive services designed to keep frail seniors in their homes and communities. The profile explicitly states that 93% of participants live safely in their homes, which aligns with the delivery of care where the patient lives.
MAZE
Maze Therapeutics
$1.45Bn
26.21
+1.31%
+74.27%
Maze Therapeutics is a clinical-stage biopharmaceutical company that uses its proprietary Compass platform for biology-based drug discovery and development. It develops therapies derived from human genetics and functional genomics, such as the APOL1 inhibitor MZE829 and the SLC6A19 inhibitor MZE782, and generates revenue through milestone payments and royalties from biotechnology partners.
HROW
Harrow
$1.44Bn
38.54
+0.73%
+3.21%
Harrow develops and markets a wide range of FDA-approved branded ophthalmic pharmaceuticals, such as IHEEZO, VEVYE, and VIGAMOX. Its primary revenue is generated from the sale of these branded prescription products for conditions like dry eye and glaucoma.
CGEM
Cullinan Therapeutics
$1.42Bn
22.09
-0.32%
+219.68%
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically T cell engagers and bispecific antibodies like CLN-978 and CLN-049. Its revenue model is based on collaboration agreements, milestone payments, and royalties from partners such as Taiho Pharmaceutical.
LBRX
Lb Pharmaceuticals
$1.42Bn
49.34
+3.83%
+185.20%
Lb Pharmaceuticals is developing LB 102, a branded prescription drug candidate for neuropsychiatric disorders like schizophrenia and bipolar depression. The company expects future revenue from the commercial sale of oral and long-acting injectable formulations of this branded pharmaceutical to healthcare providers and patients.
TNDM
Tandem Diabetes Care
$1.38Bn
19.90
-2.59%
+60.61%
Tandem Diabetes Care designs and manufactures durable insulin pump systems, specifically the t:slim X2 and Mobi platforms, which are therapeutic medical devices used for insulin delivery.
ALMS
Alumis
$1.38Bn
11.10
-2.29%
+137.18%
Alumis is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically monoclonal antibodies like lonigutamab and targeted inhibitors for immune-mediated diseases. Its business model focuses on biology-based drug discovery and development using a precision data analytics platform integrating genomic and proteomic information.
OMDA
Omada Health
$1.38Bn
22.77
+2.15%
-3.35%
Omada Health delivers virtual care programs for chronic conditions like diabetes and hypertension, employing health coaches and licensed physical therapists to provide remote clinical care. Its revenue is generated through contracts with employers and health plans for these remote consultation and monitoring services.
AZTA
Azenta
$1.37Bn
31.33
+0.48%
+6.67%
Azenta sells a broad portfolio of life sciences research tools, including automated storage systems, cryogenic systems, and consumables like racks, tubes, and plates. These products are sold to pharmaceutical, biotechnology, and academic research institutions for sample exploration and management.
OMER
Omeros
$1.37Bn
18.95
-0.84%
+353.35%
Omeros is a biotechnology company that develops therapies derived from biological science, specifically protein therapeutics and antibodies such as YARTEMLEA (narsoplimab-wuug) and OMS1029. Its revenue is generated from the sale of these biologic products and collaboration payments from partners like Novo Nordisk.
VOR
Vor Biopharma
$1.36Bn
25.05
+3.34%
-37.38%
Vor Biopharma is a clinical-stage biopharmaceutical company developing telitacicept, which is described as a recombinant fusion protein. This biology-based drug discovery and development for autoimmune diseases fits the Biotechnology classification.
ORIC
Oric Pharmaceuticals
$1.33Bn
12.86
+0.94%
+19.41%
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically targeting PRC2 dysregulation and EGFR exon 20 mutations. Its revenue is currently derived from upfront payments, milestone payments, and royalties from licensing and collaboration agreements, which is characteristic of the Biotechnology industry.
PNTG
Pennant
$1.32Bn
38.00
-1.40%
+53.91%
Pennant Group operates 172 home health and hospice agencies and 63 senior living communities, providing care where the patient lives. Its revenue is derived from nursing, therapy, and residential care reimbursed by Medicare, Medicaid, and private pay sources.
EYE
2nd
National Vision Holdings
$1.32Bn
16.74
-0.77%
-26.55%
The company provides clinical eye exam services to consumers, which are delivered in an outpatient clinic setting within its retail locations.
DRTS
Alpha Tau Medical
$1.32Bn
15.03
+2.80%
+330.66%
Alpha Tau Medical designs and manufactures the Alpha DaRT® technology, which consists of radioactive sources and specialized applicators used as localized radiation therapy for solid tumors. These products are therapeutic medical devices sold to oncology centers and hospitals for the treatment of cancers such as pancreatic adenocarcinoma and glioblastoma multiforme.
NUTX
Nutex Health
$1.32Bn
193.24
-2.25%
+125.01%
Nutex Health owns and operates a network of micro hospitals and specialty hospitals that provide 24/7 inpatient care, emergency room treatment, and behavioral health support. Revenue is primarily generated from facility fees paid by federal agencies, private insurers, and patients for these inpatient and surgical services.
SDGR
2nd
Schrodinger
$1.32Bn
20.09
-2.99%
+5.90%
The company operates a Drug Discovery segment where it develops a proprietary pipeline of therapeutic candidates and conducts collaborative research with biopharma partners, earning revenue from milestones and royalties.
MGTX
MeiraGTx Holdings
$1.31Bn
13.89
-0.57%
+89.50%
MeiraGTx is a clinical stage genetic medicines company developing gene therapies for disorders such as Parkinson's disease and inherited retinal diseases. Its core technology involves the delivery of genetic medicines and a proprietary riboswitch platform for controlling gene expression.
PRCT
PROCEPT BioRobotics
$1.30Bn
22.76
+6.50%
-39.85%
PROCEPT BioRobotics designs and manufactures the AquaBeam and HYDROS Robotic Systems, which are image-guided robotic platforms used for the surgical treatment of benign prostatic hyperplasia. These are therapeutic and surgical medical devices sold to hospitals and ambulatory surgery centers.
IART
Integra Lifesciences Holdings
$1.30Bn
16.72
+1.70%
+10.51%
Integra designs and manufactures therapeutic and surgical medical devices, including neurosurgical instruments, ICP monitoring systems, and cranial stabilization devices. These products are sold to hospitals and surgery centers for use in neurosurgery and neurocritical care.
IMTX
Immatics
$1.28Bn
9.56
+1.06%
+75.41%
Immatics is a clinical-stage company developing T cell receptor (TCR) based immunotherapies, specifically autologous engineered T cell therapies (ACTengine) and bispecific molecules. Its core platform focuses on genetic and cellular modification to target intracellular cancer antigens in solid tumors.
MLTX
MoonLake Immunotherapeutics
$1.28Bn
15.01
-1.18%
-74.87%
MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing Nanobody-based treatments, which are biological therapies. Its primary asset, SLK, is a tri-specific Nanobody designed to inhibit IL-17A and IL-17F cytokines for inflammatory diseases.
JBIO
Jade Biosciences
$1.26Bn
19.90
+0.25%
+165.69%
Jade Biosciences is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies, such as JADE101 and JADE201, which are biologics. Its business model focuses on the research and development of these biological therapies for autoimmune diseases.
REPL
Replimune
$1.26Bn
15.04
-1.64%
+155.35%
Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies derived from an engineered strain of herpes simplex virus 1 (HSV-1). Its product candidates, such as RP1 and RP2, are biologics designed to selectively replicate in tumors and stimulate immune responses.
MNKD
Mannkind
$1.26Bn
4.06
+2.53%
-23.97%
MannKind is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically inhaled insulin (Afrezza) and inhaled treprostinil (Tyvaso DPI). Its revenue is driven by the sale of these biologic products and royalties from collaborations with partners like United Therapeutics.
THRM
2nd
Gentherm
$1.25Bn
40.70
+1.70%
+13.43%
The company's Medical segment designs and manufactures patient temperature management systems for hyperthermia and hypothermia therapy used in intensive care and surgical procedures.
ANRO
Alto Neuroscience
$1.25Bn
35.56
-2.20%
+913.11%
Alto Neuroscience is a clinical-stage biopharmaceutical company developing therapies for neuropsychiatric disorders such as major depressive disorder and schizophrenia. Its revenue model currently consists of upfront fees, milestone payments, and royalties from collaborations with partners like Sanofi and Cerecor, which is characteristic of biotechnology developers.
AORT
Artivion
$1.25Bn
25.58
-0.08%
-40.95%
Artivion designs and manufactures therapeutic and surgical medical devices, specifically aortic stent grafts (e.g., E-vita Open NEO), mechanical heart valves (On-X), and surgical sealants (BioGlue). These products are sold to hospitals and healthcare facilities for use by surgeons in cardiac and vascular procedures.
JANX
Janux Therapeutics
$1.24Bn
20.24
+2.22%
-12.15%
Janux Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically T cell engagers and immunomodulators using its TRACTr, TRACIr, and ARM platforms. Its revenue is currently derived from collaboration and milestone payments from partners like Merck and Bristol Myers Squibb, which is characteristic of biotechnology developers.
UTI
2nd
Universal Technical Institute
$1.23Bn
22.25
+3.01%
-19.09%
Through its Concorde Career Colleges segment, the company provides education and training in allied health, dental, nursing, and diagnostic fields, including clinical externships in clinical settings.
OPK
Opko Health
$1.22Bn
1.64
+1.86%
+18.84%
The company develops, manufactures, and markets branded prescription drugs such as the growth hormone NGENLA and the kidney disease treatment Rayaldee. It generates significant revenue from direct sales of these branded pharmaceuticals and royalty payments from partners like Pfizer.
CRVS
Corvus Pharmaceuticals
$1.21Bn
14.39
-1.77%
+156.05%
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically monoclonal antibodies like mupadolimab. Its revenue model currently relies on collaboration, milestone payments, and royalties, which is characteristic of biotechnology developers.
GDRX
2nd
GoodRx Holdings
$1.18Bn
3.48
-1.42%
-18.69%
The company generates revenue from telehealth visits offered via its subscription services, where patients pay for virtual consultations with healthcare professionals.
CLYM
Climb Bio
$1.18Bn
15.52
+6.37%
+536.07%
Climb Bio is a clinical-stage biotechnology company developing monoclonal antibodies, specifically budoprutug (anti-CD19) and CLYM116 (anti-APRIL). Its revenue is derived from collaboration agreements, milestone payments, and royalties, which is characteristic of the H-02 Biotechnology industry.
BVS
Bioventus
$1.18Bn
14.07
-2.02%
+99.86%
Bioventus designs and manufactures therapeutic and surgical medical devices, including peripheral nerve stimulation devices (StimRouter, Talismann), ultrasonic surgical platforms (neXus BoneScalpel), and ultrasound bone stimulation systems (EXOGEN). These products are sold to physicians, hospitals, and ambulatory surgical centers for use in orthopedic and neurosurgical procedures.
USPH
U S Physical Therapy
$1.18Bn
79.15
+0.50%
-5.49%
The company operates outpatient physical, speech, and occupational therapy clinics. Revenue is primarily generated from patient service payments for care delivered in these outpatient clinic settings.
GLUE
Monte Rosa Therapeutics
$1.18Bn
13.84
-3.76%
+176.80%
Monte Rosa Therapeutics is a clinical-stage biotechnology company that develops therapies derived from biological science, specifically molecular glue degraders. Its revenue is currently derived from collaboration and milestone payments from partners like Novartis and Roche, which is characteristic of the H-02 classification.
KURA
Kura Oncology
$1.18Bn
13.25
+0.76%
+57.18%
Kura Oncology discovers, develops, and markets branded prescription small-molecule therapeutics, specifically the FDA-approved drug KOMZIFTI for the treatment of NPM1-mutated AML. Its revenue is derived from the commercial sale of this branded pharmaceutical product.
STAA
Staar Surgical
$1.18Bn
23.47
-0.47%
-14.09%
Staar Surgical designs and manufactures implantable lenses for the eye, specifically the Implantable Collamer Lens (ICL) and associated delivery systems. These are therapeutic surgical medical devices used by ophthalmic surgeons to treat myopia, hyperopia, and astigmatism.
AVNS
Avanos Medical
$1.17Bn
24.99
+0.04%
+110.35%
Avanos Medical designs and manufactures therapeutic and surgical medical devices, including ON-Q and ambIT surgical pain pumps, Game Ready cold and compression therapy systems, and COOLIEF radiofrequency ablation products. These products are sold to hospitals and ambulatory care centers for clinical use in pain management and recovery.
SANA
Sana Biotechnology
$1.15Bn
3.85
-1.79%
+28.76%
Sana Biotechnology focuses on developing engineered cell therapies, specifically using a hypoimmune technology for stem cell derived islet cells (SC451) and a fusogen platform for in vivo CAR T cell generation (SG293). These activities involve modifying and replacing cells and delivering genetic material, which aligns directly with the Gene and Cell Therapy industry.
TDOC
Teladoc Health
$1.14Bn
6.28
-2.94%
-19.07%
Teladoc Health provides virtual primary, urgent, chronic, and mental health services, as well as online counseling via BetterHelp. Its revenue is derived from per-member-per-month access fees from employers and insurers, as well as visit fees and self-pay subscriptions.
SVRA
Savara
$1.10Bn
5.37
+0.00%
+50.00%
Savara is a clinical-stage biopharmaceutical company developing molgramostim inhalation solution (MOLBREEVI), which is described as an inhaled biologic delivering recombinant human granulocyte macrophage colony stimulating factor. This fits the H-02 classification for companies researching and developing therapies derived from biological science, such as recombinant proteins.
IRMD
Iradimed
$1.07Bn
83.45
-3.63%
+18.20%
Iradimed designs and manufactures therapeutic and surgical medical devices, specifically MRI compatible infusion pumps, patient vital signs monitors, and ferromagnetic detection devices. These products are sold to hospitals and acute care facilities to enable safe MRI procedures for critically ill patients.
OKYO
OKYO Pharma
$1.06Bn
1.57
+1.95%
-30.22%
OKYO Pharma is a clinical-stage biopharmaceutical company developing urcosimod, which is described as a lipidated peptide. This falls under the biotechnology category as it involves therapies derived from biological science (peptides) and the company's revenue model relies on milestone payments and potential biologic product sales.
FDMT
4D Molecular Therapeutics
$1.05Bn
14.97
+1.84%
+131.38%
The company focuses on developing genetic medicines using a proprietary Therapeutic Vector Evolution platform to create adeno-associated virus (AAV) vectors. Its product candidates, such as 4D-150 for retinal diseases and 4D-710 for cystic fibrosis, are designed to deliver transgenes to modify or replace genetic function.
PCRX
Pacira BioSciences
$1.05Bn
26.35
-0.94%
-3.05%
The company's primary revenue is derived from branded prescription pharmaceuticals, specifically EXPAREL (a long-acting local analgesic) and ZILRETTA (an extended-release corticosteroid), which together account for the vast majority of its total revenue.
PROK
Prokidney
$1.03Bn
2.01
+4.69%
-14.83%
ProKidney is developing rilparencel, an autologous cell therapy that involves expanding a patient's own renal cells outside the body and re-injecting them. This core platform of cellular modification and therapy fits the definition of Gene and Cell Therapy.
ABUS
Arbutus Biopharma
$1.02Bn
5.15
+0.59%
+28.43%
Arbutus Biopharma is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically imdusiran, a GalNAc conjugated RNAi therapeutic. Its revenue model consists of licensing agreements, milestone payments, and royalties from biologic products like Alnylam's ONPATTRO.
GERN
Geron
$1.01Bn
1.57
+3.97%
+12.14%
Geron is a biopharmaceutical company that developed RYTELO (imetelstat), a first-in-class telomerase inhibitor derived from biological science to treat myelodysplastic syndromes. The company generates revenue from the sale of this biologic product to healthcare providers and hospitals.
MNPR
Monopar Therapeutics
$1.00Bn
117.56
-0.84%
+224.66%
Monopar is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically MNPR 101, which is a humanized monoclonal antibody used for oncology imaging and therapy. The company's revenue model includes licensing agreements, milestone payments, and royalties, which is characteristic of biotechnology developers.
CSTL
Castle Biosciences
$1.00Bn
32.91
+0.80%
+41.85%
Castle Biosciences operates as a molecular diagnostics company that provides clinical laboratory testing services, such as DecisionDx-Melanoma and TissueCypher, to clinicians. Its revenue is generated from diagnostic-testing service fees billed to third-party payors, Medicare, and patients.
LXRX
Lexicon Pharmaceuticals
$1.00Bn
2.24
-0.88%
+107.41%
Lexicon is a biopharmaceutical company that discovers, develops, and markets branded prescription drugs, specifically commercializing INPEFA for heart failure. Its revenue is derived from the sales of this branded pharmaceutical product and licensing agreements for other small-molecule drug candidates.
IMMX
Immix Biopharma
$995.06Mn
13.91
+0.58%
+526.58%
Immix Biopharma is a clinical-stage company developing NXC 201, which is an autologous CAR T (chimeric antigen receptor T cell) therapy. Its core business is based on the N GENIUS platform for cell therapy and genetic modification to treat AL amyloidosis.
AMPH
Amphastar Pharmaceuticals
$985.90Mn
23.18
-2.77%
-21.13%
Amphastar primarily develops, manufactures, and commercializes technically challenging generic injectable, inhalation, and intranasal products. Its revenue is driven by the sale of these generic and specialty pharmaceuticals to hospitals, clinics, and pharmacies.
CADL
Candel Therapeutics
$972.79Mn
12.78
-1.46%
+150.10%
Candel Therapeutics develops viral immunotherapies using engineered adenovirus and herpes simplex virus vectors to modify the tumor microenvironment. Its core platforms, including aglatimagene and linoserpaturev, are based on genetic modification of viruses to induce systemic anti-tumor immunity.
SGP
SpyGlass Pharma
$967.94Mn
28.94
-0.17%
—
SpyGlass Pharma is a biopharmaceutical company developing branded prescription drug delivery systems, specifically the BIM IOL System and BIM DRS, to treat glaucoma and ocular hypertension using the drug bimatoprost. Its revenue model is based on the sale of these branded pharmaceutical products and associated reimbursement for the physician-administered drug component.
QDEL
QuidelOrtho
$954.15Mn
13.97
+0.29%
-49.40%
QuidelOrtho manufactures and sells clinical diagnostic equipment and tests, including the VITROS platform for clinical chemistry and the ORTHO VISION platform for immunohematology. Its revenue model is based on the sale of instruments and a recurring stream of assays, reagents, and consumables.
DSGN
Design Therapeutics
$947.46Mn
15.14
+0.73%
+147.79%
Design Therapeutics is a clinical-stage company developing GeneTAC molecules, which it explicitly describes as a 'novel class of small molecule' therapeutics. Because its core platform focuses on small-molecule drug discovery for branded prescription use (targeting diseases like Friedreich ataxia and Huntington's disease) rather than biologics, it fits the Pharmaceuticals category.
CBLL
Ceribell
$944.88Mn
24.72
+0.61%
+112.92%
Ceribell sells the Ceribell System, which includes the Clarity recorder device and AI-powered algorithms for the rapid diagnosis and continuous monitoring of seizures and delirium. These are clinical diagnostic tools sold to hospitals for point-of-care EEG testing, fitting the description of diagnostic equipment and assays.
INMD
InMode
$944.68Mn
14.91
+0.47%
+2.76%
InMode designs and manufactures energy-based minimally invasive surgical medical treatment solutions, such as the BodyTite and Morpheus8 platforms, which are used for face and body contouring. These products are therapeutic and surgical medical devices sold to plastic surgeons, dermatologists, and OB/GYNs.
ARDX
Ardelyx
$941.78Mn
3.78
+1.89%
-41.94%
Ardelyx is a biopharmaceutical company that researches, develops, and commercializes therapies derived from biological science, specifically its lead asset tenapanor. The company generates revenue from the sales of biologic-based products like IBSRELA and XPHOZAH, as well as milestone payments and royalties from collaboration partners such as Kyowa Kirin and Fosun Pharma.
NNNN
Anbio Biotechnology
$941.05Mn
6.54
-0.91%
-86.17%
Anbio Biotechnology designs and sells in vitro diagnostic kits and instruments, including real-time PCR and chemiluminescence immunoassay products. Its revenue is derived from the sale of these diagnostic machines and the associated assays to hospitals, clinics, and laboratories.
OLMA
Olema Pharmaceuticals
$940.11Mn
10.75
+0.19%
+70.91%
Olema Pharmaceuticals is a clinical-stage company developing novel small molecule therapeutics, such as palazestrant and OP-3136, for breast cancer. Its business model focuses on the discovery, development, and eventual commercialization of branded prescription drugs.
WVE
Wave Life Sciences
$939.33Mn
4.86
+3.40%
-40.59%
Wave Life Sciences is a clinical-stage biotechnology company developing therapies derived from biological science, specifically RNA-based medicines including siRNA and antisense oligonucleotides. Its revenue is currently generated through collaboration agreements, milestone payments, and royalties from partners like GSK and Takeda.
IVA
Inventiva
$923.67Mn
4.78
-1.24%
-17.16%
Inventiva is a clinical-stage company developing lanifibranor, which is described as an oral small molecule therapy. Because the lead candidate is a small-molecule drug rather than a biologic, it fits the Pharmaceuticals category for branded prescription drug development.
RIGL
Rigel Pharmaceuticals
$909.15Mn
48.67
+0.35%
+22.87%
Rigel is described as a biotechnology company that develops therapies derived from biological science, specifically targeting signaling pathways for hematologic disorders and cancer. Its revenue is derived from the sale of biologic-based products like TAVALISSE, REZLIDHIA, and GAVRETO, as well as collaboration and milestone payments.
TBPH
Theravance Biopharma
$886.30Mn
17.08
+0.00%
+24.40%
Theravance Biopharma is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically targeting respiratory diseases. Its revenue is driven by biologic-related product sales, profit-sharing agreements for YUPELRI, and milestone payments from partnerships with GSK and Viatris.
AHCO
AdaptHealth
$884.62Mn
6.49
+1.09%
-29.53%
AdaptHealth provides healthcare-at-home solutions, including the delivery, setup, and clinical support of medical equipment and supplies directly in patients' homes. Its business model focuses on home-based care for patients managing chronic conditions like sleep apnea, respiratory disease, and diabetes, as well as those transitioning from acute care to home.
STTK
Shattuck Labs
$881.20Mn
6.79
-2.44%
+430.47%
Shattuck Labs is a clinical-stage biotechnology company developing monoclonal and bispecific antibodies, such as SL-325 and SL-425, which are biologic therapies. Its revenue model is typical for biotech, relying on equity financing and potential collaboration payments and royalties.
AVR
Anteris Technologies Global
$880.59Mn
9.04
+3.67%
+120.49%
Anteris Technologies Global designs and manufactures therapeutic medical devices for cardiac care, specifically the DurAVR® THV System and the ComASUR® Delivery System for treating aortic stenosis. These are surgical implants and delivery tools used in transcatheter aortic valve replacement (TAVR) procedures.
BBNX
Beta Bionics
$873.54Mn
19.42
-2.51%
-3.38%
Beta Bionics designs and manufactures the iLet Bionic Pancreas, which is a therapeutic medical device used for insulin delivery in patients with diabetes. The company generates revenue from the sale of this device to individual patients and healthcare providers.
TALK
Talkspace
$870.58Mn
5.25
+0.00%
+101.92%
Talkspace delivers clinical behavioral healthcare, including virtual psychotherapy and psychiatry, remotely via a web and mobile platform. It generates revenue through per-member-per-month fees and subscriptions from payors, enterprises, and individual consumers for these remote clinical services.
NGNE
Neurogene
$870.51Mn
38.60
+2.63%
+94.26%
Neurogene is a clinical-stage company developing genetic medicines, specifically using an adeno-associated virus vector to deliver the MECP2 gene for the treatment of Rett syndrome. Its core EXACT technology focuses on regulating transgene expression, which is a hallmark of gene therapy development.
ACRS
Aclaris Therapeutics
$862.72Mn
6.17
+3.70%
+199.51%
Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically monoclonal antibodies and bispecific antibodies like bosakitug and ATI-052. Its revenue model consists of upfront licensing fees, milestone payments, and royalties from collaborations with partners such as Biosion.
ANNX
Annexon
$850.32Mn
4.87
+0.62%
+126.51%
Annexon is a biopharmaceutical company developing targeted immunotherapies, specifically complement protein C1q inhibitors, which are biological therapies. The company is a clinical-stage developer with no current product revenue, focusing on biological science to treat neuroinflammatory diseases.
AVTX
Avalo Therapeutics
$838.47Mn
19.23
+1.21%
+89.27%
Avalo Therapeutics is a clinical-stage biotechnology company developing abdakibart (AVTX-009), which is described as a humanized IgG monoclonal antibody. Its business model focuses on the research and development of biologics to treat immune-mediated inflammatory diseases.
SIBN
Si-Bone
$826.90Mn
18.50
-0.75%
+14.06%
SI-BONE designs and manufactures titanium implants and associated instruments used to stabilize bone and promote fusion in the sacroiliac joint. These are therapeutic and surgical medical devices sold to hospitals, ambulatory surgery centers, and physicians.
CTMX
CytomX Therapeutics
$808.41Mn
3.71
+0.82%
+76.67%
CytomX is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically masked biologics including antibody-drug conjugates (ADCs), T-cell engagers, and cytokines. Its revenue is generated through collaboration and milestone payments from partners like Amgen and Bristol Myers Squibb, which is characteristic of the Biotechnology industry.
CYRX
2nd
Cryoport
$800.75Mn
15.81
-0.32%
+86.00%
Cryoport provides bioprocessing and research-related tools through its IntegriCell cryopreservation services and BioStorage solutions used for preclinical and early-stage clinical materials.
AUTL
Autolus Therapeutics
$795.30Mn
2.24
-2.18%
+55.56%
Autolus Therapeutics develops and commercializes T cell therapies, specifically the CD19-directed chimeric antigen receptor T cell therapy AUCATZYL (obecabtagene autoleucel). Its core business is based on a T cell programming technology platform used to engineer cells for the treatment of cancer and autoimmune diseases.
ZURA
Zura Bio
$789.99Mn
6.23
+5.95%
+200.97%
Zura Bio is a clinical-stage biotechnology company developing antibody-based therapies, such as tibulizumab and torudokimab, derived from biological science. Its revenue model relies on equity offerings, debt, and potential milestone payments from partnerships with larger pharmaceutical firms.
PHAR
Pharming
$787.99Mn
11.23
-2.01%
-21.80%
Pharming is a biotechnology company that develops and commercializes therapies derived from biological science, specifically RUCONEST®, which is a recombinant C1 esterase inhibitor protein replacement therapy. Its revenue is generated from the sale of these biologic products for rare and ultra-rare diseases.
ODD
2nd
Oddity Tech
$782.63Mn
13.75
-2.69%
-77.87%
The company operates METHODIQ, a medical telehealth platform that provides personalized skin assessments and high-efficacy dermatology treatments via a tracking app.
AURA
Aura Biosciences
$782.31Mn
7.56
+2.58%
+19.24%
Aura Biosciences is a clinical-stage biotechnology company developing bel-sar, a virus-like drug conjugate (VDC) derived from biological science for targeted cancer therapy. Its revenue model is based on the development of these biologic candidates and potential future milestone payments or royalties.
VREX
Varex Imaging
$780.16Mn
18.51
-0.05%
+67.97%
Varex designs and manufactures X-ray tubes, flat panel and photon counting detectors, and image processing software used in computed tomography, mammography, and fluoroscopy. These products are sold to OEMs and end-users for clinical diagnostic radiology modalities.
COLL
Collegium Pharmaceutical
$764.69Mn
23.53
-0.72%
-40.57%
Collegium develops and markets branded prescription drugs, including Jornay PM for ADHD and Xtampza ER for pain management. Its revenue is generated from the sale of these branded pharmaceutical products to wholesale distributors.
PHAT
Phathom Pharmaceuticals
$760.67Mn
9.50
+4.97%
-20.83%
Phathom Pharmaceuticals develops and markets branded prescription drugs, specifically VOQUEZNA, VOQUEZNA DUAL PAK, and VOQUEZNA TRIPLE PAK for gastrointestinal diseases. Its revenue is generated solely from the sale of these branded pharmaceutical products in the United States.
VSTM
Verastem
$741.95Mn
8.20
+2.76%
-13.68%
Verastem discovers, develops, and markets branded prescription drugs, specifically the AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer. Its revenue is derived principally from the sales of this branded pharmaceutical product in the United States.
ZVRA
Zevra Therapeutics
$735.84Mn
12.40
-1.12%
+38.86%
Zevra Therapeutics develops and markets branded prescription drugs for rare diseases, specifically MIPLYFFA for Niemann-Pick disease type C and OLPRUVA for urea cycle disorders. Its revenue is derived from the sale of these branded pharmaceutical products through specialty pharmacy distribution channels.
GYRE
Gyre Therapeutics
$727.39Mn
6.86
+6.52%
-15.10%
Gyre Therapeutics is a commercial-stage company that develops and markets branded small-molecule prescription drugs. Its revenue is driven by the sale of branded therapies such as ETUARY® (pirfenidone), Etorel® (nintedanib), and Contiva® (avatrombopag).
ASMB
Assembly Biosciences
$726.52Mn
36.60
+1.30%
+57.01%
Assembly Biosciences is a biotechnology company that researches and develops antiviral therapies, such as the HDV entry inhibitor ABI-6250 and the HBV capsid assembly modulator ABI-4334. Its revenue is derived from collaboration and licensing agreements, including upfront and milestone payments from Gilead Sciences.
BBOT
BridgeBio Oncology Therapeutics
$719.43Mn
8.98
+0.90%
-8.74%
BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically targeting the RAS and PI3Kα oncogenes. Its pipeline includes investigational agents such as BBO-8520, BBO-11818, and BBO-10203, which are currently in phase 1 clinical trials.
MLAB
Mesa Laboratories
$715.03Mn
127.78
-0.58%
+98.63%
Mesa Laboratories designs and manufactures life sciences tools, including the MassARRAY system for genomic testing and Gyrolab systems for protein analysis and peptide synthesis. These products, along with their associated chips, panels, and reagents, are sold to biopharma R&D teams, academic laboratories, and clinical research labs.
IRWD
Ironwood Pharmaceuticals
$703.92Mn
4.26
-0.70%
+243.55%
Ironwood Pharmaceuticals is described as a biotechnology company that develops therapies derived from biological science, specifically mentioning apraglutide, which is a peptide analog. Its revenue model includes biologic product sales, royalties, and milestone payments from partners like AstraZeneca and Astellas.
SLN
Silence Therapeutics
$689.33Mn
14.59
-1.35%
+178.97%
Silence Therapeutics is a biotechnology company that develops therapies derived from biological science, specifically using siRNA and its proprietary mRNAi GOLD™ platform to target messenger RNA. Its revenue is currently derived from collaboration and milestone payments from pharmaceutical partners like AstraZeneca and Hansoh for its RNAi-based drug candidates.
SSII
SS Innovations International
$682.58Mn
3.41
+0.59%
-50.58%
The company designs, manufactures, and markets the SSi Mantra Surgical Robotic System, which is used for various surgical procedures including urology and cardiac surgeries. Its revenue is derived from the sale of these surgical robots and related instruments.
ALLO
Allogene Therapeutics
$680.33Mn
1.97
-0.51%
+77.48%
Allogene Therapeutics develops genetically engineered allogeneic T cell product candidates, specifically CAR T therapies, which involve modifying cells to treat cancer and autoimmune diseases. Its core platform relies on gene editing technologies from Cellectis (TALEN) and Arbor Biotechnologies (CRISPR) to create off-the-shelf cellular therapies.
WOOF
2nd
Petco Health & Wellness Company
$671.30Mn
2.70
+7.14%
-21.05%
The company provides clinical veterinary care through approximately 300 full-service veterinary hospitals and 1,600 Vetco clinics, delivering preventive and therapeutic care in an outpatient setting.
AQST
Aquestive Therapeutics
$670.23Mn
5.34
-0.19%
+5.53%
Aquestive Therapeutics is a pharmaceutical company that develops and markets branded prescription drugs, such as Libervant for epilepsy rescue. Its business model focuses on creating alternative administration methods for complex molecules to replace standard of care therapies.
PRME
Prime Medicine
$668.73Mn
3.70
-0.27%
+10.78%
Prime Medicine focuses on developing genetic medicines using Prime Editing, a next-generation gene editing technology designed to modify genomic DNA. The company is developing in vivo programs for Wilson disease and alpha 1 antitrypsin deficiency, as well as an ex vivo program for chronic granulomatous disease.
ALT
Altimmune
$665.10Mn
3.42
+5.88%
-7.07%
Altimmune is a biopharmaceutical company developing pemvidutide, a peptide engineered as a dual agonist of glucagon and GLP1 receptors. Its revenue model is typical of clinical-stage biotechnology firms, deriving from licensing arrangements and collaborative agreements while developing biologic-based therapies.
EVO
Evotec SE
$661.34Mn
1.86
-2.11%
-44.81%
Evotec provides integrated drug discovery and preclinical development services, including target identification, lead optimization, and IND enabling programs. The company generates the vast majority of its revenue (79% in 2025 and 94% in 2024) through fee-for-service and FTE-based contracts for pharmaceutical and biotechnology partners.
CRMD
CorMedix
$654.73Mn
8.43
-0.47%
-34.14%
CorMedix develops and markets branded prescription pharmaceuticals, most notably DefenCath, an FDA-approved antimicrobial catheter lock solution. The company also sells a portfolio of branded anti-infective agents such as REZZAYO and VABOMERE, and the cardiovascular product TOPROL XL.
NVCT
Nuvectis Pharma
$653.76Mn
24.49
+0.49%
+285.67%
Nuvectis Pharma is a clinical-stage company developing small molecule drug candidates, specifically NXP900, which is a targeted small molecule inhibitor of SRC and YES1 kinases. Because its lead candidates are small-molecule drugs rather than biologics, it fits the Pharmaceuticals classification for branded prescription drug development.
OCS
Oculis Holding AG
$635.80Mn
12.17
+0.00%
-25.61%
Oculis Holding AG is a biopharmaceutical company developing therapies derived from biological science, specifically Licaminlimab, which is a single chain antibody fragment. The company's core business is the research and development of these biologic-based drug candidates for ophthalmic diseases.
ANGO
Angiodynamics
$633.85Mn
15.20
-1.75%
+43.13%
AngioDynamics designs and manufactures therapeutic and surgical medical devices, including the Auryon Atherectomy System, NanoKnife ablation platforms, and VenaCure EVLT laser systems. These products are sold to hospitals and clinics for treating cardiovascular disease and cancer.
OABI
OmniAb
$629.54Mn
4.33
-8.84%
+170.62%
OmniAb's core business is a biotechnology platform that uses engineered transgenic animals and biological intelligence to discover and optimize antibodies and other target-binding proteins for human therapeutics. Its revenue is primarily derived from license agreements, milestones, and royalties from pharmaceutical and biotech partners developing biologic products.
CTNM
Contineum Therapeutics
$625.71Mn
16.70
-4.95%
+57.84%
Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing therapies derived from biological science, specifically modulating biological pathways like the lysophosphatidic acid 1 receptor. Its revenue is derived from collaboration agreements, licensing deals, and milestone payments, such as its agreement with Johnson & Johnson for the PIPE-307 asset.
MPLT
MapLight Therapeutics
$625.67Mn
13.77
+4.79%
—
MapLight Therapeutics is a biopharmaceutical company developing branded prescription drug candidates for CNS disorders, such as ML-007C-MA for schizophrenia and Alzheimer's disease psychosis. Its pipeline consists of small-molecule agonists and antagonists, such as the M1/M4 muscarinic agonist and the GPR52 positive allosteric modulator ML-009.
EOLS
Evolus
$613.93Mn
9.30
+2.76%
+26.02%
Evolus develops and markets branded prescription products for aesthetic use, specifically Jeuveau (a botulinum toxin) and Evolysse (hyaluronic acid gels). These are branded pharmaceutical products sold to licensed aesthetic practitioners for the treatment of frown lines and wrinkles.
ARVN
Arvinas
$613.17Mn
9.39
+0.86%
+18.86%
Arvinas is a clinical-stage biotechnology company that develops therapies using its proprietary PROTAC platform to degrade disease-causing proteins. Its revenue is derived from collaboration and licensing agreements with partners like Pfizer and Novartis, including upfront payments and milestones.
CTKB
Cytek Biosciences
$610.92Mn
4.70
+0.00%
+19.29%
Cytek Biosciences develops and sells flow cytometry instruments, such as the Aurora and Northern Lights systems, and reagents like cFluor and Tonbo for high-dimensional single cell analysis. Its primary customers are pharmaceutical companies, biopharma firms, and academic research centers using these tools for drug discovery and research in oncology and immunology.
VALN
Valneva SE
$609.12Mn
7.02
+1.89%
-17.61%
Valneva SE is a specialty vaccine company that develops and commercializes biologic therapies, specifically prophylactic vaccines like IXIARO, DUKORAL, and IXCHIQ. Its business model relies on the sale of these biologic products and the development of a clinical pipeline including candidates for Lyme disease and Zika virus.
STLN
Starling Oncology
$595.78Mn
5.93
-0.67%
+83.59%
The company operates a network of oncology clinics providing physician services, infusion therapy, and radiation therapy in an outpatient setting. It generates revenue through fee-for-service billing for these procedures and value-based payments from payers for managing outpatient cancer care.
TLRY
2nd
Tilray Brands
$592.57Mn
4.50
-0.66%
-60.87%
Through its subsidiary CC Pharma, the company operates a distribution segment that purchases, resells, and distributes pharmaceutical products and medical cannabis to pharmacies and hospitals in Germany and Europe.
TECX
Tectonic Therapeutic
$591.48Mn
30.75
+2.77%
+88.30%
Tectonic Therapeutic is a clinical-stage biotechnology company developing therapies derived from biological science, specifically therapeutic proteins and antibodies such as the TX45 Fc-relaxin fusion molecule and TX2100 VHH-Fc fusion antagonist antibody. Its core business is biology-based drug discovery using its proprietary GEODe platform to target G-protein coupled receptors.
CABA
Cabaletta Bio
$588.32Mn
3.47
-0.29%
+125.32%
Cabaletta Bio focuses on developing engineered T cell therapies, specifically chimeric antigen receptor (CAR) T cells, to treat autoimmune diseases. Its lead product candidate, rese cel, is a CAR T construct designed to modify the immune system, which fits the definition of gene and cell therapy.
KIDS
Orthopediatrics
$585.12Mn
22.41
-0.80%
+7.22%
OrthoPediatrics designs and manufactures therapeutic and surgical medical devices, specifically orthopedic implants, instruments, and robotic insertion tools for pediatric patients. Its revenue is primarily generated from the sale of trauma plating systems, flexible intramedullary nails, and spinal implants.
BNTC
Benitec Biopharma
$582.91Mn
12.68
+1.93%
-9.43%
Benitec Biopharma is a clinical-stage company developing BB301, an adeno-associated virus (AAV) based gene therapy. Its core business is based on a 'silence and replace' platform designed to modify or replace genes to treat Oculopharyngeal Muscular Dystrophy.
SGMT
Sagimet Biosciences
$581.07Mn
10.94
+0.18%
+50.90%
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing FASN inhibitors, such as denifanstat and TVB-3567, which are therapies derived from biological science. Its revenue model consists of licensing agreements and milestone payments from collaborators like Ascletis BioScience Co. Ltd.
CBIO
Crescent Biopharma
$579.55Mn
20.88
+2.35%
+57.82%
Crescent Biopharma is a clinical-stage biotechnology company developing therapies derived from biological science, specifically bispecific antibodies and antibody drug conjugates. Its revenue is currently derived from upfront payments, milestone payments, and royalties from collaboration and licensing agreements with partners.
DDD
2nd
3D Systems
$574.87Mn
3.46
+3.90%
+68.78%
The company provides surgical planning tools, implants, and instrumentation for hospitals and medical device companies through its Healthcare Solutions segment.
DCTH
Delcath Systems
$570.81Mn
16.48
+0.00%
+48.47%
Delcath Systems designs and manufactures therapeutic medical devices, specifically the CHEMOSAT hepatic delivery system and the HEPZATO KIT drug/device combination, used for percutaneous hepatic perfusion procedures to treat liver cancers. These products are sold to hospitals and cancer centers for surgical/interventional use.
SPRY
ARS Pharmaceuticals
$558.84Mn
5.62
-0.88%
-47.43%
ARS Pharmaceuticals develops and markets neffy, a branded prescription intranasal epinephrine spray for the emergency treatment of anaphylaxis. Revenue is generated from the sale of this branded pharmaceutical product to wholesalers and pharmacies.
IMUX
Immunic
$557.36Mn
13.11
+2.74%
+70.26%
Immunic is a biotechnology company researching and developing therapies derived from biological science, specifically targeting immunological targets for neurologic and gastrointestinal diseases. Its pipeline includes candidates like vidofludimus calcium (IMU 838) and IMU 856, which are currently in clinical stages.
BWAY
Brainsway
$554.20Mn
14.15
-2.48%
+80.48%
BrainsWay designs and manufactures the Deep Transcranial Magnetic Stimulation (Deep TMS) system, which is a therapeutic medical device used to treat major depressive disorder and OCD. Revenue is generated from the sale, leasing, and servicing of these hardware systems to psychiatrists, hospitals, and clinics.
CAPR
Capricor Therapeutics
$546.22Mn
9.40
+1.29%
+49.68%
Capricor Therapeutics focuses on the development of cell and exosome based therapeutics, specifically its lead candidate Deramiocel for Duchenne muscular dystrophy. The company's core platform is based on cellular modification and delivery, which aligns with the Gene and Cell Therapy classification.
FLGT
Fulgent Genetics
$542.87Mn
19.73
+0.41%
-10.40%
Fulgent Genetics operates a laboratory services business that performs anatomic pathology and molecular diagnostics, generating the majority of its revenue from fees charged for laboratory tests performed for hospitals, reference labs, and institutional clients.
CERS
Cerus
$521.95Mn
2.59
+0.78%
+94.74%
Cerus designs and manufactures the INTERCEPT Blood System, which includes the INTERCEPT Illuminator (an LED-based device) used to inactivate pathogens in blood components. These are therapeutic/treatment devices sold to blood centers and hospitals.
OVID
Ovid Therapeutics
$517.32Mn
2.80
+0.72%
+110.53%
Ovid Therapeutics is a biopharmaceutical company focused on discovering and developing small molecule medicines, such as the GABA aminotransferase inhibitor OV329, to treat brain disorders. Its business model targets the development of branded prescription pharmaceuticals for indications including epilepsy, psychosis, and neuropsychiatric manifestations.
ANL
Adlai Nortye
$515.40Mn
15.01
+1.76%
+743.26%
Adlai Nortye is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically antibody-drug conjugates (AN4035) and tri-specific antibody fusion proteins (AN8025). Its revenue is currently derived from collaboration and milestone payments from partners like Eisai and ASK Pharm, which is characteristic of biotechnology developers.
NPCE
NeuroPace
$510.81Mn
14.90
+1.02%
+59.19%
NeuroPace designs and manufactures the RNS System, a brain responsive neurostimulation device used to treat drug resistant epilepsy. The company generates revenue from the sale of the neurostimulator, cortical and depth leads, and related accessories to hospitals and epilepsy centers.
XFOR
X4 Pharmaceuticals
$510.43Mn
4.04
+0.00%
+10.99%
X4 Pharmaceuticals develops and markets branded prescription drugs, specifically the small-molecule oral antagonist XOLREMDI (mavorixafor) for the treatment of WHIM syndrome. Its revenue is derived from the sale of this branded pharmaceutical product and associated licensing and royalty payments.
SENS
Senseonics Holdings
$509.09Mn
9.63
-2.73%
+6.53%
Senseonics designs and manufactures the Eversense CGM system, which consists of an implantable sensor and a removable smart transmitter. These are therapeutic/monitoring medical devices used for diabetes management, fitting the description of medical devices.
PRTA
Prothena Corp Public
$508.13Mn
9.82
+2.29%
+17.04%
Prothena is a clinical-stage biotechnology company that develops therapies derived from biological science, specifically targeting protein dysregulation and misfolded proteins using its CYTOPE® platform. Its revenue is derived from collaboration and milestone payments from partners like Roche, Novo Nordisk, and Bristol Myers Squibb for biologic candidates targeting Parkinson's and Alzheimer's diseases.
KYTX
Kyverna Therapeutics
$507.95Mn
8.25
-1.20%
+127.27%
Kyverna Therapeutics focuses on developing cell therapies, specifically its lead product candidate mivcel, which is an autologous CD19 directed chimeric antigen receptor (CAR) T cell therapy. The company's core platform is based on genetic and cellular modification to treat autoimmune diseases like stiff person syndrome and generalized myasthenia gravis.
DRUG
Bright Minds Biosciences
$497.55Mn
65.16
-4.20%
+48.26%
Bright Minds Biosciences is a biotechnology company developing therapies derived from biological science, specifically targeting serotonin receptor subtypes for neurological and psychiatric disorders. Its lead candidate BMB 101 and other pipeline compounds (BMB 105, BMB 201, BMB 202) are developed using a proprietary platform of biased agonists and structure-based drug design.
TCMD
Tactile Systems Technology
$496.48Mn
21.87
-0.64%
+65.18%
The company designs and manufactures therapeutic medical devices, specifically pneumatic compression systems (Flexitouch Plus, Entre Plus, Nimbl) for lymphedema and the AffloVest wearable vest for airway clearance. These are treatment devices used for chronic vascular and respiratory conditions, fitting the definition of therapeutic medical devices.
CNTN
2nd
Canton Strategic Holdings
$494.45Mn
2.28
+1.33%
-52.20%
The company maintains a Biotechnology Research and Development segment through its subsidiary Gravitas, focusing on biologic therapeutic candidates like GV104 and GV023 for immunology and inflammation.
KMDA
Kamada
$492.64Mn
8.54
+3.26%
+20.96%
Kamada is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically immunoglobulins extracted and purified from human plasma. Its proprietary products include KEDRAB, GLASSIA, and CYTOGAM, and it generates significant revenue from these biologic sales and royalties from Takeda.
EVH
Evolent Health
$488.42Mn
4.32
+1.17%
-54.48%
Evolent Health delivers specialty care management services for complex conditions like cancer and cardiovascular disease, supporting physicians and providers in delivering evidence-based care. Its revenue is generated through service fees and capitation arrangements for managing patient care in outpatient and specialty settings.
PBYI
Puma Biotechnology
$488.03Mn
9.55
+1.49%
+86.16%
Puma Biotechnology is a biopharmaceutical company that researches and commercializes therapies derived from biological science, specifically focusing on oncology. Its lead product, NERLYNX (neratinib), and its investigational drug alisertib are developed to treat HER2 positive breast cancer and small cell lung cancer.
RGNX
Regenxbio
$484.23Mn
8.94
-2.83%
-5.10%
REGENXBIO is a clinical-stage company focused on developing gene therapies using adeno-associated virus (AAV) vectors for retinal, neuromuscular, and neurodegenerative diseases. Its core business revolves around the NAV Technology Platform for genetic modification and the development of candidates like sura vec.
RLMD
Relmada Therapeutics
$472.55Mn
4.43
+1.37%
+223.36%
Relmada Therapeutics is a clinical-stage biotechnology company developing therapies such as sepranolone, a neurosteroid epimer, and NDV-01. The company's business model is based on biology-based drug discovery and development, with anticipated future revenue from product sales, milestones, and royalties.
SRTA
Strata Critical Medical
$470.64Mn
5.32
-0.93%
+28.19%
Strata provides clinical services including surgical organ recovery, organ placement, and cardiac care perfusion to transplant centers and cardiovascular surgery centers. These services are delivered in outpatient or clinic settings (such as hospitals and organ procurement organizations) and are billed on a fee-for-service or retainer basis.
NEUP
Neuphoria Therapeutics
$469.97Mn
3.77
+0.27%
-71.00%
Neuphoria is a clinical-stage biotechnology company developing therapies for neuropsychiatric disorders, specifically its lead candidate BNC210. Its revenue is derived from collaboration and milestone payments from partners like Merck, which is characteristic of the H-02 biotechnology classification.
AVIR
Atea Pharmaceuticals
$467.59Mn
5.83
+0.17%
+68.50%
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically a proprietary platform of nucleosides and nucleotides. Its lead candidates, bemnifosbuvir and AT 587, are nucleotide analogs being developed to treat hepatitis C and hepatitis E.
CCCC
C4 Therapeutics
$462.13Mn
3.76
+0.53%
+40.82%
C4 Therapeutics is a clinical-stage biopharmaceutical company that develops therapies derived from biological science, specifically targeted protein degradation using its TORPEDO platform. Its revenue is currently derived from collaboration and milestone payments from partners like Pfizer, Merck KGaA, and Roche, which is characteristic of biotechnology developers.
OCGN
Ocugen
$461.10Mn
1.36
+0.74%
+32.04%
Ocugen's core business is centered on its Modifier Gene Therapy Platform, which uses AAV5 vectors to deliver nuclear hormone receptor genes for treating inherited retinal diseases like retinitis pigmentosa and Stargardt disease. This focus on genetic modification for therapeutic purposes aligns directly with the Gene and Cell Therapy industry.
SGHT
Sight Sciences
$456.88Mn
8.35
-0.36%
+123.86%
Sight Sciences designs and manufactures therapeutic and surgical medical devices, specifically the OMNI Surgical System and SION Surgical Instrument for glaucoma and the TearCare system for dry eye disease. These products are sold to healthcare providers for use in minimally invasive surgical procedures.
ARCT
Arcturus Therapeutics Holdings
$449.65Mn
15.82
+1.67%
-5.61%
Arcturus is a biotechnology company focused on developing therapies and vaccines derived from biological science, specifically using a proprietary self-amplifying mRNA platform. Its revenue is generated from biologic product sales of its COVID-19 vaccine KOSTAIVE, as well as collaboration and milestone payments from partners like CSL Seqirus.
CYPH
2nd
Cypherpunk Technologies
$446.07Mn
2.42
+6.61%
+734.48%
Through its subsidiary Leap Therapeutics, the company develops antibody therapies for cancer, specifically leveraging a proprietary anti-DKK1 antibody platform for oncology treatments.
MCTA
2nd
Charming Medical
$445.47Mn
29.35
+0.00%
—
The company employs registered Chinese medicine practitioners to provide TCM-inspired therapies for health improvement needs, including menstrual irregularities, menopausal care, and breast health, delivered in its wellness centers.
EVMN
Evommune
$445.18Mn
12.27
+2.16%
—
Evommune is a clinical-stage biotechnology company developing therapies derived from biological science, specifically the fusion protein EVO301 which inhibits the IL 18 cytokine. Its revenue model consists of upfront payments, milestone payments, and royalties from partnerships with firms like Dermira, Maruho, and AprilBio.
DNA
Ginkgo Bioworks Holdings
$442.79Mn
6.95
+0.00%
-38.66%
Ginkgo Bioworks operates as a platform providing R&D services, cell engineering solutions, and high-throughput data generation for external sponsors. Its revenue model is based on service fees, milestone payments, and value-share arrangements for projects involving therapeutics, vaccines, and industrial chemicals for customers like Biogen and Novo Nordisk.
ARTV
Artiva Biotherapeutics
$441.03Mn
11.19
+0.63%
+259.81%
Artiva Biotherapeutics is a clinical-stage company developing cell-based therapies, specifically allogeneic off-the-shelf natural killer (NK) cell therapies like AlloNK and CAR-NK programs (AB-201 and AB-205). Its core platform is based on cellular modification and the use of cord blood starting material to treat autoimmune diseases and cancers.
RZLT
Rezolute
$441.02Mn
4.58
+0.88%
-37.94%
Rezolute is a biotechnology company developing ersodetug, which is described as a human monoclonal antibody. The company's core business is the research and development of this biologic therapy for rare diseases like congenital and tumor-associated hyperinsulinism.
MTLS
2nd
Materialise
$440.64Mn
7.46
+6.12%
+51.32%
Materialise designs and manufactures personalized medical devices, including 3D printed surgical guides and patient-specific implants, sold to healthcare providers and medtech companies.
BIOA
BioAge Labs
$439.00Mn
9.59
+0.95%
+102.32%
BioAge Labs is a clinical-stage biopharmaceutical company developing therapies for metabolic diseases using a proprietary platform based on multi-omic data. Its revenue is derived from collaboration agreements and milestones with pharmaceutical partners like Lilly and Novartis, which is characteristic of biotechnology developers.
IKT
Inhibikase Therapeutics
$436.43Mn
2.50
-0.79%
+46.20%
Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing IKT-001, an oral prodrug of imatinib, which is a small-molecule branded prescription drug candidate for pulmonary arterial hypertension.
PRLD
Prelude Therapeutics
$435.73Mn
5.46
+4.00%
+378.95%
Prelude Therapeutics is a biotechnology company focused on discovering and developing therapies derived from biological science, specifically protein degraders and antibody-drug conjugates (ADCs). Its revenue model is based on strategic partnerships, upfront payments, and milestone payments from collaborations with partners like Incyte and AbCellera.
FENC
Fennec Pharmaceuticals
$434.07Mn
12.39
-1.27%
+34.97%
Fennec is described as a specialty pharmaceutical company focusing on a niche indication (cisplatin-induced ototoxicity). It generates revenue from the sale of its specialty therapy, PEDMARK, and through licensing and distribution agreements for the same product.
CMPX
Compass Therapeutics
$428.61Mn
2.38
+0.42%
-29.38%
Compass Therapeutics is a clinical-stage biopharmaceutical company developing antibody-based therapeutics, specifically using its proprietary StitchMabs platform to create bispecific antibodies. Its revenue is derived from collaboration and milestone payments from partners like ABL Bio and Adimab, which is characteristic of the Biotechnology industry.
